<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000071.pub2" GROUP_ID="STROKE" ID="226299073014380255" MERGED_FROM="" MODIFIED="2010-02-10 15:36:36 +0100" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0003" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2010-02-10 15:36:36 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2009-10-04 15:56:49 +0100" MODIFIED_BY="Hazel Fraser">Patches of different types for carotid patch angioplasty</TITLE>
<CONTACT MODIFIED="2010-02-10 15:36:36 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="16532" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Rothwell</LAST_NAME><EMAIL_1>peter.rothwell@clneuro.ox.ac.uk</EMAIL_1><URL>www.stroke.ox.ac.uk</URL><ADDRESS><DEPARTMENT>Stroke Prevention Research Unit, Department of Clinical Neurology</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Level 6, West Wing, John Radcliffe Hospital</ADDRESS_1><ADDRESS_2>Headington</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 617158</PHONE_1><FAX_1>+44 1865 617161</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-02-10 15:36:36 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="17162" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kittipan</FIRST_NAME><LAST_NAME>Rerkasem</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>krerkase@mail.med.cmu.ac.th</EMAIL_1><MOBILE_PHONE>+66 858668484</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Surgery, Faculty of Medicine</DEPARTMENT><ORGANISATION>Chiang Mai University</ORGANISATION><CITY>Chiang Mai</CITY><ZIP>50200</ZIP><COUNTRY CODE="TH">Thailand</COUNTRY><PHONE_1>+66 053 94 5532</PHONE_1><FAX_1>+66 053 946139</FAX_1></ADDRESS></PERSON><PERSON ID="16532" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Rothwell</LAST_NAME><EMAIL_1>peter.rothwell@clneuro.ox.ac.uk</EMAIL_1><URL>www.stroke.ox.ac.uk</URL><ADDRESS><DEPARTMENT>Stroke Prevention Research Unit, Department of Clinical Neurology</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Level 6, West Wing, John Radcliffe Hospital</ADDRESS_1><ADDRESS_2>Headington</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 617158</PHONE_1><FAX_1>+44 1865 617161</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-01-12 14:10:23 +0000" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="29" MONTH="11" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="8" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="1" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="1996"/>
</DATES>
<WHATS_NEW MODIFIED="2010-02-10 14:32:27 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-02-10 14:32:27 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="17" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>Change of authorship.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-01-12 16:22:34 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="17" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>Difference between this review and the previous version: two new trials (<LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>) comparing synthetic with venous patching, and another three trials comparing Dacron and other synthetic material (<LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Albrecht_x002d_Fruh-1998" TYPE="STUDY">Albrecht-Fruh 1998</LINK>; <LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>) have been added to the review. These provided more data on the long-term outcome between Dacron and other synthetic material. The review now has 13 included studies with data for 2083 operations. The conclusions are similar to the previous version of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-10-07 10:35:13 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-07 10:35:13 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="9" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-10 14:20:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="2" YEAR="2003"/>
<DESCRIPTION>
<P>Differences between this review and the previous version: four new trials (AbuRahma 1996; Hayes 2001; Katz 1996; O'Hara 2002) comparing synthetic with venous patching have recently been added to the review. Data on a total of 1280 operations are now available for analysis. A further trial 'Jugular vein versus PTFE patch for carotid endarterectomy' by Deriu and Grego is due to be reported in the next year and has been added to the 'Awaiting assessment' section and will be included in the review as soon as possible.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-10-01 10:30:55 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Oxford University Medical Research Fund (MRF)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-10-01 10:30:55 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>NHS Executive Research and Development Directorate</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-10-01 10:29:43 +0100" MODIFIED_BY="[Empty name]">
<NAME>Northern Neurological Center, Faculty of Medicine, Chiang Mai University, Thailand</NAME>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-10-01 10:30:55 +0100" MODIFIED_BY="[Empty name]">
<NAME>Division of Vascular Surgery Unit, Department of Surgery, Faculty of Medicine, Chiang Mai University, Thailand</NAME>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-01-27 09:51:48 +0000" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2010-01-12 14:18:20 +0000" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-09-10 14:24:00 +0100" MODIFIED_BY="[Empty name]">Patches of different types for carotid patch angioplasty</TITLE>
<SUMMARY_BODY MODIFIED="2010-01-12 14:18:20 +0000" MODIFIED_BY="Hazel Fraser">
<P>About 20% of strokes result from narrowing of the carotid artery (the main artery supplying blood to the brain). Carotid endarterectomy is an operation that involves opening the carotid artery to remove this narrowing and therefore reduce the risk of stroke. However, there is a 5% to 10% risk of the operation itself causing a stroke. There is evidence that, at the end of the operation when the artery is being closed, inserting a patch into the gap in the artery reduces the risk of strokes. Patches are made out of either synthetic material or the patient's own vein. This review aimed to assess whether one type of patch was better than another; however, the 13 trials reviewed did not provide clear evidence about which type of patch material is best. Vein patches may rupture with potentially fatal consequences and synthetic materials are vulnerable to infection. Further research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-01-27 09:49:05 +0000" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND MODIFIED="2010-01-27 09:44:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Carotid patches for carotid endarterectomy may be made from an autologous vein or synthetic material. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-09-10 14:21:28 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the safety and efficacy of different materials for carotid patch angioplasty.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-01-27 09:44:44 +0000" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group trials register (last searched 3 August 2009), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 3, 2009), MEDLINE (1966 to November 2008), EMBASE (1980 to November 2008) and Index to Scientific and Technical Proceedings (1980 to 2008). We handsearched relevant journals and conference proceedings, checked reference lists, and contacted experts in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised and quasi-randomised trials comparing one type of carotid patch with another for carotid endarterectomy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-01-12 14:14:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>Two review authors independently assessed eligibility, trial quality, and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-01-27 09:48:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>We included 13 trials involving a total of 2083 operations; seven trials compared vein closure with PTFE closure, and six compared Dacron grafts with other synthetic materials. In most trials a patient could be randomised twice and have each carotid artery randomised to different treatment groups. There were no significant differences in the outcomes between vein patches and synthetic materials apart from pseudoaneurysms where there were fewer associated with synthetic patches than vein patches (odds ratio (OR) 0.09, 95% confidence interval (CI) 0.02 to 0.49). However, the numbers involved were small and the clinical significance of this finding is uncertain. Compared to other synthetic patches, Dacron was associated with a higher risk of: perioperative combined stroke and transient ischaemic attack (P = 0.03); restenosis at 30 days (P = 0.004); perioperative stroke (P = 0.07) and perioperative carotid thrombosis (P = 0.1). During follow-up for more than one year, there were also significantly more strokes (P = 0.03), stroke/death (P = 0.02) and arterial restenoses (P &lt; 0.0001) with Dacron but the numbers of outcomes were small and the significance of this finding is uncertain.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-01-27 09:49:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>The number of outcome events is too small to allow reliable conclusions to be drawn and more trial data are required to establish whether any differences do exist. Nevertheless, there is some evidence that other synthetic (e.g. PTFE) patches may be superior to collagen impregnated Dacron grafts in terms of perioperative stroke rates and restenosis. Pseudoaneurysm formation may be more common after use of a vein patch compared with a synthetic patch.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-01-27 09:51:48 +0000" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2010-01-12 14:19:59 +0000" MODIFIED_BY="Hazel Fraser">
<P>Carotid endarterectomy has been shown in large, well-conducted randomised controlled trials (RCTs) to reduce the risk of stroke in patients with recently symptomatic, severe (greater than 70%) internal carotid artery stenosis (<LINK REF="REF-ECST-1991" TYPE="REFERENCE">ECST 1991</LINK>; <LINK REF="REF-ECST-1998" TYPE="REFERENCE">ECST 1998</LINK>; <LINK REF="REF-NASCET-1991" TYPE="REFERENCE">NASCET 1991</LINK>; <LINK REF="REF-NASCET-1998" TYPE="REFERENCE">NASCET 1998</LINK>). There is also some evidence that it may be beneficial for some categories of asymptomatic patients (<LINK REF="REF-ACAS-1995" TYPE="REFERENCE">ACAS 1995</LINK>). What is less clear at present is whether different surgical techniques affect the outcome, although there is increasing evidence that the use of carotid patch angioplasty is superior to primary closure in reducing the risk of restenosis and improving both short and long-term clinical outcome (<LINK REF="REF-Counsell-1998" TYPE="REFERENCE">Counsell 1998</LINK>). Consequently, many vascular surgeons use carotid patching either routinely or selectively. However, there is still considerable debate over the choice of patch material. Vein patching (usually harvested from the saphenous vein and sometimes from the jugular vein) is favoured by some on the basis that a non-randomised comparison suggested that it was better at preventing stroke or death (<LINK REF="REF-Fode-1986" TYPE="REFERENCE">Fode 1986</LINK>). It also has the advantages of being easily available, easy to handle and possibly has a greater resistance to infection. Synthetic material, such as Dacron or polytetrafluoroethylene (PTFE), is favoured by others who feel that it offers a lower risk of patch rupture (<LINK REF="REF-Murie-1994" TYPE="REFERENCE">Murie 1994</LINK>) and aneurysmal dilatation (<LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>), and also that it spares the morbidity associated with saphenous vein harvesting and leaves the vein which may be required for coronary bypass grafting at a later date. It is also possible that one type of synthetic material is better than another. For example, AbuRahma et al found PTFE resulted in significantly fewer perioperative carotid thromboses and strokes than Dacron (<LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>). Finally, there are less commonly used materials such as bovine pericardium (<LINK REF="REF-Kim-2001" TYPE="REFERENCE">Kim 2001</LINK>) which have yet to be widely accepted.</P>
<P>The most reliable evidence on the best material to use comes from randomised trials and so we have reviewed the randomised trials comparing different types of patch material in carotid endarterectomy.</P>
</BACKGROUND>
<OBJECTIVES>
<P>We wished to assess the safety and efficacy of different types of patch material in carotid patch angioplasty. The primary hypothesis was that synthetic material was associated with a lower risk of patch rupture than venous patches, but that venous patches were associated with lower risk of perioperative stroke and early and late infection.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-01-27 09:50:29 +0000" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2010-01-27 09:49:36 +0000" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES MODIFIED="2010-01-27 09:49:28 +0000" MODIFIED_BY="Hazel Fraser">
<P>We sought to identify all unconfounded randomised trials in which one type of carotid patch was compared to another. Quasi-randomised trials in which allocation to different treatment regimens was not adequately concealed (e.g. allocation by alternation, date of birth, hospital number, day of the week or by using an open random number list) could also be included. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-01-12 14:22:10 +0000" MODIFIED_BY="Hazel Fraser">
<P>We considered trials which included any type of patient undergoing carotid endarterectomy eligible, whether the initial indication for endarterectomy was symptomatic or asymptomatic carotid disease.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-10-01 12:50:02 +0100" MODIFIED_BY="[Empty name]">
<P>We sought to identify all trials comparing one type of patch material with another in carotid endarterectomy. The materials currently available include saphenous vein (harvested from either the ankle or the groin), Dacron, polytetrafluoroethylene (PTFE) polyester or polyurethane.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-01-27 09:49:36 +0000" MODIFIED_BY="Hazel Fraser">
<P>We aimed to extract from each trial the number of patients originally allocated to each treatment group to allow an intention-to-treat analysis. Within each treatment group we then extracted the number of patients:</P>
<UL>
<LI>who died within 30 days of the operation and during subsequent follow-up; we tried to classify each death as stroke-related or not;</LI>
<LI>who had any stroke (fatal, non-fatal, contralateral, ipsilateral, brainstem, haemorrhage, or infarct) within 30 days of the operation and during subsequent follow-up; we also performed a separate analysis of strokes ipsilateral to the endarterectomy.</LI>
</UL>
<P>We also tried to extract the number of arteries that:</P>
<UL>
<LI>became occluded within 30 days of the operation;</LI>
<LI>developed a significant complication related to surgery, e.g. haemorrhage from or rupture of the artery, infection of the endarterectomy site, or cranial nerve palsy;</LI>
<LI>developed restenosis greater than 50% (including occlusion), or a pseudoaneurysm (as defined in each trial) during follow-up.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-01-27 09:49:42 +0000" MODIFIED_BY="Hazel Fraser">
<P>See the 'Specialized register' section in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A> module.</P>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Managing Editor in August 2009. We also updated the electronic searches and handsearched additional issues of relevant journals as follows.</P>
<OL>
<LI>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 3, 2009), MEDLINE (1966 to November 2008) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), EMBASE (1980 to November 2008) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and Index to Scientific and Technical Proceedings (1980 to November 2008), which was searched using the terms "carotid" and ("trial* or random*").</LI>
<LI>We handsearched the following journals including conference supplements:</LI>
<OL>
<LI>
<I>Annals of Surgery</I> (1981 to September 2008);</LI>
<LI>
<I>Annals of Vascular Surgery</I> (1994 to September 2008);</LI>
<LI>
<I>Cardiovascular Surgery</I> (now <I>Vascular</I>) (1994 to September 2008);</LI>
<LI>
<I>European Journal of Vascular Surgery</I> (now <I>European Journal of Vascular and Endovascular Surgery</I>) (1987 to September 2008);</LI>
<LI>
<I>Journal of Vascular Surgery</I> (1994 to September 2008);</LI>
<LI>
<I>Stroke</I> (1994 to September 2008).</LI>
</OL>
<LI>We reviewed the reference lists of all relevant studies.</LI>
<LI>We contacted experts in the field to identify further published and unpublished studies.</LI>
<LI>For the previous version of the review:</LI>
<OL>
<LI>we handsearched the following journals including conference supplements:</LI>
<OL>
<LI>
<I>American Journal of Surgery</I> (1994 to 2001);</LI>
<LI>
<I>British Journal of Surgery</I> (1985 to 2001);</LI>
<LI>
<I>World Journal of Surgery</I> (1978 to 2001).</LI>
</OL>
<LI>we handsearched abstracts of the following meetings for the years 1995 to 2001:</LI>
<OL>
<LI>AGM of the Vascular Surgical Society (UK);</LI>
<LI>AGM of the Association of Surgeons of Great Britain and Ireland;</LI>
<LI>American Heart Association Stroke Conference;</LI>
<LI>Annual Meeting of the Society for Vascular Surgery (USA);</LI>
<LI>The European Stroke Conference.</LI>
</OL>
</OL>
</OL>
<P>We did not apply any language restriction in the searches and arranged translation of all possibly relevant non-English language publications.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-01-27 09:50:29 +0000" MODIFIED_BY="Hazel Fraser">
<P>
<B>Selection of studies</B>
</P>
<P>One review author (KR) selected those trials that met the inclusion criteria and another review author (PMR) independently reviewed these decisions. We resolved all disagreements through discussion. </P>
<P>
<B>Data extraction and management</B>
</P>
<P>The same two review authors also assessed the methodological quality of each trial. We decided not to use a scoring system to assess quality but simply to record the following details: the randomisation method, the blinding of the clinical and Doppler assessments, whether outcomes were reported for all patients originally randomised in each group irrespective of whether they received the operation they were allocated to or whether the patient was excluded after randomisation, and the number of patients lost to follow up. We sought data on the number of outcome events in all patients originally randomised to allow an intention-to-treat analysis. We triple-checked all data extraction. In addition, we also extracted details about the patients included in the trial, the inclusion and exclusion criteria, the comparability of the treatment and control groups for important prognostic factors, the type of patch, the type of anaesthetic, the use of shunts, and the use of antiplatelet therapy during follow-up. Much of the above data were not available from the publications, and so we sought further information from the trialists in all cases; however, we did not always receive a response.</P>
<P>
<B>Assessment of risk of bias in included studies</B>
</P>
<P>All of the trials randomised the artery rather than the patient and all included patients who had bilateral carotid endarterectomies. It was, therefore, possible for a single patient to have both types of patch material. In these patients, it would be difficult to relate death or stroke to one particular procedure. In the previous version of this review, in trials where it was possible for a patient to have both procedures, death and any stroke were only analysed in those who had unilateral procedures or the same procedure to both arteries. Where data were not obtainable from the authors of relevant trials the whole trial was excluded from the analysis (<LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>). Of the five studies published since 1995, two ensured that patients undergoing more than one operation were assigned the same closure method (<LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>) whereas three did not (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>). However, most patients who undergo more than one operation will have a period of at least 30 days between the procedures, therefore short-term results are likely to be reliable regardless of how data are analysed. Only one of the later studies reported long-term follow-up (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>) but the number of bilateral operations are small compared with the total number of operations carried out and unlikely to bias the results significantly. Therefore, this trial was retained but this should be born in mind when interpreting results.</P>
<P>A separate analysis of only strokes ipsilateral to the operated artery was also performed for each artery. However, the total number of strokes was very similar to the number of ipsilateral strokes, since in the majority of studies all the strokes were ipsilateral. Arterial complications such as occlusion, haemorrhage from the endarterectomy site, restenosis, infection at the operation site, or pseudoaneurysm formation were analysed for all arteries rather than patients. The analyses based on arteries assumed that, in patients who had bilateral endarterectomies, outcome events in each carotid artery were independent.</P>
<P>
<B>Measures of treatment effect</B>
</P>
<P>We calculated proportional risk reductions based on a weighted estimate of the odds ratio (OR) using the Peto method (<LINK REF="REF-APT-1994" TYPE="REFERENCE">APT 1994</LINK>). We calculated absolute risk reductions from the crude risks of each outcome in all trials combined.</P>
<P>
<B>Assessment of heterogeneity</B>
</P>
<P>We assessed heterogeneity between study results using the I<SUP>2 </SUP>statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). This examined the percentage of total variation across studies due to heterogeneity rather than to chance. Values of I<SUP>2 </SUP>over 75% indicate a high level of heterogeneity.</P>
<P>
<B>Sensitivity analysis</B>
</P>
<P>Since foreknowledge of treatment allocation might lead to biased treatment allocation and exaggerated treatment effects (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), separate sensitivity analyses of those trials where allocation concealment was secure and those where it was less secure were performed in the first version of this review. However, since no significant difference was found between the trials with different allocation techniques, and because no studies in this later review were quasi-randomised, we did not plan to carry out sensitivity analyses for this version of the review.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-01-27 09:51:34 +0000" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2010-01-27 09:50:39 +0000" MODIFIED_BY="Hazel Fraser">
<P>The previous version of this review (<LINK REF="REF-Bond-2004" TYPE="REFERENCE">Bond 2004</LINK>) included eight trials involving a total of 1480 operations. Since that time there have been many retrospective reports examining different patch types. However, these only included five relevant randomised trials of a sufficient standard to be included in this review and increased the total number of trials to 13 with 2083 operations available for analysis. Two of the five later trials compared vein to PTFE (<LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>) and polyester patch (<LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>), one compared Dacron with PTFE patching (<LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>) and the rest compared Dacron with other synthetic materials, namely polyurethane patch (<LINK REF="STD-Albrecht_x002d_Fruh-1998" TYPE="STUDY">Albrecht-Fruh 1998</LINK>) and bovine pericardium (<LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>). One pre-1995 and one post-1995 trial had three arms; saphenous vein patching, PTFE patching and primary closure (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>). Only the results from the vein patching and PTFE patching group are included in this review.</P>
<P>Four trials compared saphenous vein harvested from the groin with synthetic patches (<LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>; <LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>). Two trials used saphenous vein from the ankle (<LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>), one trial alternately used vein from the jugular and from the saphenous vein at the ankle (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>) and one trial used vein from the external jugular vein (<LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>). One trial did not specify a site (<LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>). In all trials the operations were all performed under general anaesthetic, and most were also performed with shunting. All patients received antiplatelet therapy perioperatively. One study used heparin reversal at the end of surgery in 30% of their synthetic closures but none in their vein closure patients (<LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>). One used it in all patients (<LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>), five used reversal in none (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>) and data were unavailable in six cases (<LINK REF="STD-Albrecht_x002d_Fruh-1998" TYPE="STUDY">Albrecht-Fruh 1998</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>; <LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>).</P>
<P>Early (within 30 days) postoperative arterial occlusion was assessed by duplex sonography or angiography in 10 trials (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Albrecht_x002d_Fruh-1998" TYPE="STUDY">Albrecht-Fruh 1998</LINK>; <LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>; <LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>) and based on symptoms only in two trials (<LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>; <LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>). During long-term follow-up, restenosis of the arteries was assessed by Duplex ultrasound in 10 trials (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Albrecht_x002d_Fruh-1998" TYPE="STUDY">Albrecht-Fruh 1998</LINK>; <LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>) and by Doppler ultrasound and intravenous digital subtraction angiography in another (<LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>). Two trials only provided data on ipsilateral strokes and it is unclear whether any other strokes occurred during follow-up (<LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>).</P>
<P>In the pre-2002 review the average age of patients involved in the trials was about 67.5 years, 60% to 80% were male and less than 36% of operations were performed for asymptomatic carotid disease. In the studies since 2002, the average age was 67.6 years, 50% to 80% were male, and 41% of the operations were performed for asymptomatic carotid disease (excluding one study which intended to do only symptomatic patients (<LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>)). One trial only included patients with narrow internal carotid arteries (less than 5 mm external diameter) and also excluded patients with recurrent carotid stenosis (<LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>), whereas two trials excluded patients with internal carotid diameters less than 4 mm (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>). All but two trials excluded patients undergoing either recurrent carotid endarterectomy or combined coronary and carotid surgery at the same time (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>; <LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>), one excluded no patients at all (<LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>) and one did not give information on exclusions (<LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>). In all but four of the trials the treatment groups were comparable for important prognostic factors. Two trials had significantly more males in the synthetic group than the vein patch group (<LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>). Another two trials had significantly different stroke rates between the two groups (<LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-01-27 09:50:44 +0000" MODIFIED_BY="Hazel Fraser">
<P>There were several significant flaws in the trials. However, the trials published after 2002 were generally of better quality than those before. Up to 2002 six out of 10 reported a method of randomisation (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>), after 2002 all three trials reported a method of randomisation (<LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>). Adequately concealed allocation was performed in seven of the 10 pre-2002 trials (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>) and after 2002 all three trials had adequately concealed allocation (<LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>). Eight trials attempted to perform blind follow-up (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Grego-2003" TYPE="STUDY">Grego 2003</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>). One trial did not blind outcome assessments and only followed the patients until hospital discharge (<LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>). As mentioned previously, one of the main flaws in all the trials was that a patient undergoing bilateral carotid endarterectomy could be randomised twice and have each carotid artery randomised to different treatment groups. In these trials, it was unclear from the published reports how many patients in each group had bilateral procedures that were different in each artery, and whether any deaths or strokes occurred in these patients. True intention-to-treat analyses were possible in seven trials (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>; <LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-01-27 09:51:34 +0000" MODIFIED_BY="Hazel Fraser">
<P>We included data from 13 trials, involving 2083 operations, in this review. The results presented may differ from those in the published reports where we have obtained additional information from the study authors. There was no statistical heterogeneity in any of the analyses except two: outcome of perioperative ipsilateral stroke and long-term arterial occlusion between Dacron and PTFE (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Operative details</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Duration of operation</HEADING>
<P>The duration of operation was not analysed statistically because there was evidence that the durations were not normally distributed. However, synthetic patching was associated with significantly longer operation times than vein patching in three trials: mean times were 128 minutes versus 112 minutes (<LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>), 105 minutes versus 89 minutes (<LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>) and 100 minutes versus 93 minutes (<LINK REF="STD-Meerwaldt-2008" TYPE="STUDY">Meerwaldt 2008</LINK>). In contrast, two other trials found vein patching was associated with (non-significantly) longer operation times than either PTFE or Dacron: mean times were 126 minutes versus 123 minutes (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>) and 105 minutes versus 103 minutes (<LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>). In the first two cases this difference was due to longer haemostasis times with PTFE. However, the difference in the second pair of trials was explained by the longer time required to harvest vein from the groin or neck. The trial that was excluded because of the lack of clinical data (<LINK REF="STD-Carney-1987" TYPE="STUDY">Carney 1987</LINK>) also reported that the time from release of the clamps to the end of the operation was significantly longer with PTFE patches (53 minutes) compared with both vein patching (41 minutes) or Dacron patching (45 minutes) because of excessive bleeding. The trials comparing Dacron with PTFE found a non-significantly higher operation time, but significantly higher haemostasis time (P &lt; 0.001) in patients patched with PTFE than Dacron (<LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>). Five trials did not give adequate data on operation time (<LINK REF="STD-Albrecht_x002d_Fruh-1998" TYPE="STUDY">Albrecht-Fruh 1998</LINK>; <LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>; <LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>; <LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>; <LINK REF="STD-O_x0027_Hara-2002" TYPE="STUDY">O'Hara 2002</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes within 30 days of operation</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Clinical outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Vein versus synthetic material</HEADING>
<P>No significant differences were seen in the rates of ipsilateral stroke (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), any stroke (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), death (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) or combined stroke and death (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) between the different patch types. However, the absolute risks of perioperative stroke (1.8%, 25/1122), death (1.0%, 14/1122) and combined stroke and death (2.4%, 27/1122) were all very low. All of the strokes were ipsilateral, but in two trials other types of stroke were not recorded. The functional outcome of stroke was not assessed in any of the trials. The small number of events make it unlikely that any differences between PTFE patching and vein patching would have been detected even if present.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Dacron versus other synthetic material</HEADING>
<P>Eight strokes occurred in the Dacron group compared with one in the other synthetic group (P = 0.07) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). There was also a significantly increased risk of perioperative combined stroke and transient ischaemic attack (P = 0.03) with Dacron compared with PTFE (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). There were three deaths in the Dacron-patched group and one in the other synthetic group (P = 1.0).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Arterial complications</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Cranial nerve injury</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>Cranial nerve palsy occurred in 3% of cases (19/630). There was no suggestion that it was more common in either group and the confidence intervals were wide.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus PTFE</HEADING>
<P>No cranial nerve palsies were reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Wound infection</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>Wound infection was non-significantly more common in the vein group compared to the synthetic patch group (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). This was due to the increased risk of groin wound infection, of which patients undergoing synthetic patching would not be at risk. However, there were no patch infections during the perioperative period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>No wound infections were reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reoperation</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>Reoperation for any reason occurred in 2.6% (33/1263) of cases and showed a non-significant trend towards being more common in the synthetic patch group (OR 1.72, 95% CI 0.85 to 3.47, P = 0.13) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Reoperations were for either patch rupture (one in the PTFE group, and two in the vein group) or wound haemorrhage (2.44%, 33/1350). One of the vein ruptures involved saphenous vein harvested from the groin and one from the ankle (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). Two of the three patch ruptures were fatal, one in each group. There was a non-significant tendency for wound haematoma to be more common in the synthetic group (OR 1.63, 95% CI 0.81 to 3.28, P = 0.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>Eight patients required reoperation, seven in the Dacron group and one in the other synthetic patch (PTFE group) (P = 0.06). All re-explorations were for suspected or proven carotid thrombosis/occlusion in seven cases and one case was due to wound haematoma (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Arterial occlusion</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>The absolute risk of arterial occlusion was 0.7% (8/1155). There was a non-significant trend to suggest that acute occlusion is more common in arteries patched with synthetic material (OR 2.16, 95% CI 0.60 to 7.78, P = 0.2) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). Five of seven studies reporting rates of arterial occlusion did so based upon perioperative duplex ultrasound whereas two reported only symptomatic occlusions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>A significant risk of restenosis or occlusion at 30 days (P = 0.01) and a non-significant increased risk of perioperative carotid thrombosis (P = 0.1) was found with Dacron compared with PTFE (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes during long-term follow-up (at least one year) including events during the first 30 days</HEADING>
<P>Three trials did not follow up patients for at least one year (<LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>; <LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>; <LINK REF="STD-Marien-2002" TYPE="STUDY">Marien 2002</LINK>) and these have been excluded from these analyses.</P>
<SUBSECTION>
<HEADING LEVEL="4">Clinical outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Ipsilateral stroke</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>There was no significant difference in the ipsilateral stroke rate between vein and other synthetic material. The overall risk of ipsilateral stroke was 3.7% (29/776) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>There was only one trial in this comparison, which showed no significant difference between two groups in terms of the ipsilateral stroke rate (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) The overall risk of ipsilateral stroke was 2.5% (5/200).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Stroke</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>There were 52 recorded strokes of any type during follow-up (overall risk 4.5%). There was no significant difference between synthetic patching and vein patching and the confidence intervals were wide (OR 1.22, 95% CI 0.70 to 2.13) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). The functional outcome of stroke was not assessed in any of the trials reporting long-term outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>A significantly higher risk of stroke at long-term follow-up was found with Dacron compared with PTFE and polyurethane patching (OR 10.58, 95% CI 1.34 to 83.43) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). The 95% CI was very wide.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Death from all causes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>There was no significant difference in case fatality between the two groups (overall risk 8.4%) but the data were insufficient to give precise results (OR 0.89, 95% CI 0.59 to 1.36) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>There were only two trials that reported this outcome, with no significant difference in death rate between Dacron and other synthetic material (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). The overall risk of death was 3.7% (29/776).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Any stroke or death</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>The risk of stroke or death in the PTFE group (10.31%, 57/457) was similar to that in the vein patch group (10.19%, 56/463) but again the confidence interval was wide due to the limited data available (OR 1.05, 95% CI 0.70 to 1.56) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>Only one study reported this outcome, showing a significant trend towards a lower stroke or death rate with PTFE than with Dacron (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>) The overall risk of ipsilateral stroke is 6.5% (13/200).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Arterial complications</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Occlusion or restenosis greater than 50%</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>Only 73 arteries (6.4%) became restenosed or occluded during follow-up so that it remains unclear whether PTFE patching reduces this risk or not. No trend favouring either vein or synthetic material was present (OR 0.98, 95% CI 0.61 to 1.57) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>Compared with Dacron patching, there was a significantly lower risk of restenosis with other synthetic materials (especially with PTFE) (OR 8.25, 95% CI 3.03 to 22.49) (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Infection</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>One artery with a PTFE patch developed an infected false aneurysm at seven months which was successfully excised. There were no other late graft infections (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>There was no trial of this comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pseudoaneurysm formation</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Vein versus synthetic material</HEADING>
<P>These data were available from four trials (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>), but no trial provided an adequate definition of a pseudoaneurysm. Two trials (<LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>; <LINK REF="STD-Ricco-1996" TYPE="STUDY">Ricco 1996</LINK>) showed significant reductions in the risk of pseudoaneurysm with PTFE patching (0.8%) compared with vein patching (11.9%) (OR 0.09, 95% CI 0.02 to 0.49) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>) and two trials did not report any pseudoaneurysms in either group (<LINK REF="STD-AbuRahma-1996" TYPE="STUDY">AbuRahma 1996</LINK>; <LINK REF="STD-Hayes-2001" TYPE="STUDY">Hayes 2001</LINK>). Moreover, the clinical significance of the reduced risk with PTFE patching was unclear. None of the pseudoaneurysms ruptured or were associated with ipsilateral strokes, and in one trial all dilatations appeared within one month of surgery and none were progressive (<LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dacron versus other synthetic patch</HEADING>
<P>There were no trial data for this comparison.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-01-27 09:51:39 +0000" MODIFIED_BY="Hazel Fraser">
<P>The results of this systematic review in 2002 were inconclusive because very few patients had been included in randomised comparisons of different types of patch. Despite having increased the number of patients in this current analysis there were still insufficient data to allow us to draw useful conclusions. There are no obvious differences in the risks of stroke or death suffered by patients receiving synthetic or venous patches (either perioperatively or during long-term follow-up), or to support the belief that synthetic patching is associated with a lower risk of patch rupture. The risk of major arterial complications such as rupture or infection was very low (less than 1%) in both groups. Any trials designed to reliably detect a reduction in the risk of rupture with synthetic patching would, therefore, need to be enormous, and even if the risks of rupture were less with synthetic patching the absolute benefits would be small. For example, assuming a baseline risk of rupture of 0.6%, over 10,000 arteries would be needed to have an 80% chance of detecting a 50% reduction in the relative risk of rupture, and this would still only prevent one rupture for every 350 operations. Pseudoaneuryms were less common in the PTFE group but these data may not be accurate because they were based on so few patients. Furthermore, the definition of pseudoaneurysm may not have been consistent between trials, and the clinical implications are unclear since there were no complications associated with pseudoaneurysm formation. It has been suggested previously that reversal of perioperative anticoagulation may reduce the risk of postoperative bleeding but may also be associated with an increased risk of perioperative stroke. The inconsistency in rates of anticoagulation reversal between the included studies may, therefore, confound interpretation of the results.</P>
<P>There is increasing evidence to support the use of routine or selective patching over primary closure during carotid endarterectomy (<LINK REF="REF-Counsell-1998" TYPE="REFERENCE">Counsell 1998</LINK>). However, this review has shown that there is little reliable evidence to guide surgeons on which patch material to use. Synthetic patches do offer the advantage of sparing the morbidity and time associated with vein harvesting (e.g. poor wound healing and pain) and ensures the vein is available for future coronary bypass grafting if required. However, the use of PTFE in patching may increase the operation time (by several minutes) mainly due to increased bleeding through the suture holes. This may be less of a problem with Dacron patching (<LINK REF="STD-Carney-1987" TYPE="STUDY">Carney 1987</LINK>). In addition, the trial by Carney and Lilly suggested that surgeons preferred the handling qualities of Dacron or vein to PTFE which they found less compliant (<LINK REF="STD-Carney-1987" TYPE="STUDY">Carney 1987</LINK>). Dacron may, therefore, be preferable to PTFE, although some people believe it carries a greater risk of thrombosis (<LINK REF="STD-Lord-1989" TYPE="STUDY">Lord 1989</LINK>) and may be more prone to infection (<LINK REF="REF-Schmitt-1986" TYPE="REFERENCE">Schmitt 1986</LINK>). Furthermore, the only good quality randomised trials that have compared the use of Dacron and other synthetic material in carotid endarterectomy (<LINK REF="STD-AbuRahma-2002" TYPE="STUDY">AbuRahma 2002</LINK>; <LINK REF="STD-AbuRahma-2007" TYPE="STUDY">AbuRahma 2007</LINK>) found a significant benefit of PTFE over Hemoshield Dacron graft in terms of 30-day stroke rate and postoperative restenosis of greater than 50%. However, they also noted a longer haemostasis time associated with PTFE.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-01-27 09:51:48 +0000" MODIFIED_BY="Hazel Fraser">
<IMPLICATIONS_PRACTICE MODIFIED="2010-01-27 09:51:48 +0000" MODIFIED_BY="Hazel Fraser">
<P>The results of this review do not support the use of vein over synthetic patch material in carotid endarterectomy. The decision of which type of patch to use, if any, remains a matter of individual preference. However, if synthetic material is used, the currently available (limited) evidence from small trials appears to suggest a better outcome with PTFE than Dacron material.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-01-12 15:37:45 +0000" MODIFIED_BY="Hazel Fraser">
<P>Further trials comparing one type of patch with another are required, but they will need large numbers of patients. More trials are required which compare different types of synthetic graft material.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-01-12 15:38:17 +0000" MODIFIED_BY="Hazel Fraser">
<P>We would like to thank the following: Hazel Fraser for searching the Cochrane Stroke Group trials register and providing regular updates of newly identified RCTs, and also Brenda Thomas for searching the Cochrane Central Register of Controlled Trials (CENTRAL). We also thank the previous authors of this review, particularly Dr Rick Bond.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-01-12 15:38:46 +0000" MODIFIED_BY="Hazel Fraser">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-01-12 15:38:40 +0000" MODIFIED_BY="Hazel Fraser">
<P>Kittipan Rerkasem: refined the protocol, performed searches, selected studies for inclusion, extracted and entered the date, and wrote the review.<BR/>Peter Rothwell: refined the protocol, performed searches, selected studies, co-ordinated the project, commented on the design of the protocol and on the final manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-01-27 09:53:44 +0000" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2010-01-27 09:53:44 +0000" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2010-01-27 09:53:44 +0000" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-AbuRahma-1996" MODIFIED="2008-09-10 14:49:34 +0100" MODIFIED_BY="[Empty name]" NAME="AbuRahma 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-10 14:49:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>AbuRahma AF, Khan JH, Robinson PA, Saiedy S, Short YS, Boland JP, et al</AU>
<TI>Prospective randomized trial of carotid endarterectomy with primary closure and patch angioplasty with saphenous vein, jugular vein, and polytetrafluoroethylene: perioperative (30 day) results</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1996</YR>
<VL>24</VL>
<PG>998-1007</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>AbuRahma AF, Robinson PA, Saiedy S, Kahn JH, Boland JP</AU>
<TI>Prospective randomized trial of carotid endarterectomy with primary closure and patch angioplasty with saphenous vein, jugular vein, and polytetrafluoroethylene: long-term follow-up</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>2</NO>
<PG>222-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AbuRahma-2002" MODIFIED="2010-01-27 09:52:58 +0000" MODIFIED_BY="Hazel Fraser" NAME="AbuRahma 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-09-15 11:56:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>AbuRahma A, Hannay S, Khan JH, Robinson PA, Hudson JK, Davis EA</AU>
<TI>Prospective randomised study of carotid endarterectomy with polytetrafluoroethylene versus collagen-impregnated Dacron (Hemashield) patching: perioperative (30-day) results</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2002</YR>
<VL>35</VL>
<PG>125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-27 09:52:58 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>AbuRahma AF, Hopkins ES, Robinson PA, Deel JT, Agarwal S</AU>
<TI>Prospective randomized trial of carotid endarterectomy with polytetrafluoroethylene versus collagen-impregnated Dacron (Hemashield) patching: late follow-up</TI>
<SO>Annals of Surgery</SO>
<YR>2003</YR>
<VL>237</VL>
<PG>885-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AbuRahma-2007" MODIFIED="2010-01-12 16:07:31 +0000" MODIFIED_BY="Hazel Fraser" NAME="AbuRahma 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-12 16:07:31 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>AbuRahma AF, Stone PA, Flaherty SK, AbuRahma Z</AU>
<TI>Prospective randomized trial of ACUSEAL (Gore-Tex) versus Hemashield-Finesse patching during carotid endarterectomy: early results</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2007</YR>
<VL>45</VL>
<PG>881-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-10-05 12:12:00 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aburahma AF, Stone PA, Elmore M, Flaherty SK, Armistead L, AbuRahma Z</AU>
<TI>Prospective randomized trial of ACUSEAL (Gore-Tex) vs Finesse (Hemashield) patching during carotid endarterectomy: long-term outcome</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>1</NO>
<PG>99-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albrecht_x002d_Fruh-1998" MODIFIED="2010-01-12 16:07:59 +0000" MODIFIED_BY="Hazel Fraser" NAME="Albrecht-Fruh 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-01-12 16:07:59 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Albrecht-Fruh G, Ktenidis K, Horsch S</AU>
<TI>Dacron versus polyurethane (PUR) patch angioplasty in carotid surgery</TI>
<SO>Perioperative Monitoring in Carotid Surgery</SO>
<YR>1998</YR>
<PG>153-7</PG>
<ED>Horsch S, Ktenidis K</ED>
<PB>Darmstadt Steinkopff Springer</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gonzalez-1994" MODIFIED="2010-01-27 09:53:15 +0000" MODIFIED_BY="Hazel Fraser" NAME="Gonzalez 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-10 14:49:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-10 14:49:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Fajardo JA, Perez JL, Mateo AM</AU>
<TI>Saphenous vein patch versus polytetrafluoroethylene patch after carotid endarterectomy</TI>
<SO>Journal of Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>523-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-27 09:53:15 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Burckhardt JL, Gonzalez-Fajardo JA, Mateo AH</AU>
<TI>Saphenous vein patch versus polytetrafluoroethylene patch after carotid endarterectomy</TI>
<SO>International Angiology</SO>
<YR>1995</YR>
<VL>14 Suppl 1</VL>
<PG>346</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grego-2003" MODIFIED="2010-01-12 16:08:31 +0000" MODIFIED_BY="Hazel Fraser" NAME="Grego 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 16:08:31 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grego F, Antonello M, Lepidi S, Bonvini S, Deriu GP</AU>
<TI>Prospective, randomized study of external jugular vein patch versus polytetrafluoroethylene patch during carotid endarterectomy: perioperative and long-term results</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>1232-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayes-2001" MODIFIED="2010-01-27 09:53:29 +0000" MODIFIED_BY="Hazel Fraser" NAME="Hayes 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-12 16:08:37 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hayes PD, Allroggen H, Steel S, Thompson MM, London NJ, Bell PR, et al</AU>
<TI>Randomized trial of vein versus Dacron patching during carotid endarterectomy: influence of patch type on postoperative embolization</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>5</NO>
<PG>994-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-27 09:53:29 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naylor R, Hayes PD, Payne DA, Allroggen H, Steel S, Thompson MM, et al</AU>
<TI>Randomized trial of vein versus Dacron patching during carotid endarterectomy: long-term results</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>5</NO>
<PG>985-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1996" NAME="Katz 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz SG, Kohl RD</AU>
<TI>Does the choice of material influence early morbidity in patients undergoing carotid patch angioplasty?</TI>
<SO>Surgery</SO>
<YR>1996</YR>
<VL>119</VL>
<PG>297-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lord-1989" NAME="Lord 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lord RSA, Raj TB, Stary DL, Nash PA, Graham AR, Goh KH</AU>
<TI>Comparison of saphenous vein patch, polytetrafluoroethylene patch, and direct arteriotomy closure after carotid endarterectomy. Part I: Perioperative results</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>521-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marien-2002" MODIFIED="2010-01-27 09:53:44 +0000" MODIFIED_BY="Hazel Fraser" NAME="Marien 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-27 09:53:44 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marien BJ, Raffetto JD, Seidman CS, LaMorte WW, Menzoian JO</AU>
<TI>Bovine pericardium vs Dacron for patch angioplasty after carotid endarterectomy. A prospective randomized study</TI>
<SO>Archives of Surgery</SO>
<YR>2002</YR>
<VL>137</VL>
<PG>785-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meerwaldt-2008" MODIFIED="2010-01-12 16:09:53 +0000" MODIFIED_BY="Hazel Fraser" NAME="Meerwaldt 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-12 16:09:53 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meerwaldt R, Lansink KW, Blomme AM, Fritschy WM</AU>
<TI>Prospective randomized study of carotid endarterectomy with Fluoropassiv thin wall carotid patch versus venous patch</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2008</YR>
<VL>36</VL>
<PG>45-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Hara-2002" MODIFIED="2010-01-26 21:37:14 +0000" MODIFIED_BY="[Empty name]" NAME="O'Hara 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Hara PJ, Hertzer NR, Mascha EJ, Krajewski LP, Clair D G, Ouriel K</AU>
<TI>A prospective, randomized study of saphenous vein patching versus synthetic patching during carotid endarterectomy</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>2</NO>
<PG>324-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ricco-1996" MODIFIED="2010-01-12 16:10:24 +0000" MODIFIED_BY="Hazel Fraser" NAME="Ricco 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-10 14:50:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Ricco J-B, Demarque C, Bouin-Pineau M-H, Camiade C</AU>
<TI>Vein patch versus PTFE patch for carotid endarterectomy. A randomized trial in a selected group of patients</TI>
<SO>Manuscript submitted to the European Journal of Vascular Surgery</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 16:10:24 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ricco JB, Gauthier J-B, Bodin-Pineau M-H</AU>
<TI>Enlargement patch after carotid endarterectomy. Polytetrafluoroethylene (PTFE) or saphenous patch? Results of a randomized study after 3 years (abstract)</TI>
<SO>Paper presented at The French Language Society of Vascular Surgery, Annual Congress of Reims</SO>
<YR>19-20 June 1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-01-12 16:11:47 +0000" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Carney-1987" NAME="Carney 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carney WI, Lilly MP</AU>
<TI>Intraoperative evaluation of PTFE, Dacron and autologous vein as carotid patch materials</TI>
<SO>Annals of Vascular Surgery</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>583-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Chyatte-1996" MODIFIED="2010-01-12 16:11:33 +0000" MODIFIED_BY="Hazel Fraser" NAME="Chyatte 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-01-12 16:11:33 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chyatte D</AU>
<TI>Perioperative microemboli during carotid endarterectomy: differences between synthetic and saphenous vein patches</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1996</YR>
<VL>6 Suppl 2</VL>
<PG>2 (Abstract 17)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruckert-2000" MODIFIED="2010-01-12 16:11:47 +0000" MODIFIED_BY="Hazel Fraser" NAME="Ruckert 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 16:11:47 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruckert RI, Obitz JG, Schwenk W, Walter M</AU>
<TI>Prospective randomized comparison of different patch materials in carotid surgery</TI>
<SO>Acta Chirurgica Austriaca</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-09-30 20:52:38 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-01-12 16:13:13 +0000" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2010-01-12 16:13:13 +0000" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-ACAS-1995" MODIFIED="2008-09-10 14:50:19 +0100" MODIFIED_BY="[Empty name]" NAME="ACAS 1995" TYPE="JOURNAL_ARTICLE">
<AU>Executive Committee for the Asymptomatic Carotid Atherosclerosis Study</AU>
<TI>Endarterectomy for asymptomatic carotid artery stenosis</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>18</NO>
<PG>1421-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APT-1994" MODIFIED="2010-01-12 16:12:08 +0000" MODIFIED_BY="Hazel Fraser" NAME="APT 1994" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists Collaboration</AU>
<TI>Collaborative overview of trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>81-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Counsell-1998" MODIFIED="2008-09-10 14:43:15 +0100" MODIFIED_BY="[Empty name]" NAME="Counsell 1998" TYPE="COCHRANE_REVIEW">
<AU>Counsell C, Salinas R, Warlow C, Naylor R</AU>
<TI>Patch angioplasty compared to primary closure in carotid endarterectomy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-09-10 14:43:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-10 14:43:04 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD000160. DOI: 10.1002/14651858.CD000160"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ECST-1991" MODIFIED="2010-01-12 16:12:26 +0000" MODIFIED_BY="Hazel Fraser" NAME="ECST 1991" TYPE="JOURNAL_ARTICLE">
<AU>European Carotid Surgery Trialists' Collaborative Group</AU>
<TI>MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>1235-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ECST-1998" NAME="ECST 1998" TYPE="JOURNAL_ARTICLE">
<AU>European Carotid Surgery Trialists Collaborative Group</AU>
<TI>Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC Eurpean Carotid Surgery Trial (ECST)</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>1379-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fode-1986" NAME="Fode 1986" TYPE="JOURNAL_ARTICLE">
<AU>Fode NC, Sundt Jr TM, Robertson JT, Peerless SJ, Shields CB</AU>
<TI>Multicenter retrospective review of results and complications of carotid endarterectomy in 1981</TI>
<SO>Stroke</SO>
<YR>1986</YR>
<VL>17</VL>
<PG>370-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-01-12 16:12:53 +0000" MODIFIED_BY="Hazel Fraser" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-2001" MODIFIED="2008-09-10 14:50:45 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kim GE, Kwon TW, Cho YP, Kim DK, Kim HS</AU>
<TI>Carotid endarterectomy with bovine patch angioplasty: a preliminary report</TI>
<SO>Cardiovascular Surgery</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>5</NO>
<PG>458-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murie-1994" MODIFIED="2008-09-10 14:43:30 +0100" MODIFIED_BY="[Empty name]" NAME="Murie 1994" TYPE="JOURNAL_ARTICLE">
<AU>Murie JA, John TG, Morris PJ</AU>
<TI>Carotid endarterectomy in Great Britain and Ireland: practice between 1984 and 1992</TI>
<SO>British Journal of Surgery</SO>
<YR>1994</YR>
<VL>81</VL>
<PG>827-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NASCET-1991" MODIFIED="2010-01-12 16:13:13 +0000" MODIFIED_BY="Hazel Fraser" NAME="NASCET 1991" TYPE="JOURNAL_ARTICLE">
<AU>North American Symptomatic Carotid Endarterectomy Trial Collaborators</AU>
<TI>Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<PG>445-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NASCET-1998" NAME="NASCET 1998" TYPE="JOURNAL_ARTICLE">
<AU>North American Symptomatic Carotid Endarterectomy Trial Collaborators</AU>
<TI>Beneficial effect of carotid endarterectomy in symptomatic patients with symptomatic moderate or severe stenosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>1415-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmitt-1986" NAME="Schmitt 1986" TYPE="JOURNAL_ARTICLE">
<AU>Schmitt DD, Bandyk DF, Pequet AJ, Towne JB</AU>
<TI>Bacterial adherence to vascular prostheses. A determinant of graft infectivity</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1986</YR>
<VL>3</VL>
<PG>732-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-09-10 14:43:33 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-10-05 12:14:11 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Bond-2004" MODIFIED="2009-10-05 12:14:11 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bond 2004" TYPE="COCHRANE_REVIEW">
<AU>Bond R, Rerkasem K, Naylor R, Rothwell PM</AU>
<TI>Patches of different types for carotid patch angioplasty</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<PG>CD000071.</PG>
<IDENTIFIERS MODIFIED="2009-10-05 12:14:11 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2009-10-05 12:14:11 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000071.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Counsell-2000" MODIFIED="2008-09-10 14:44:22 +0100" MODIFIED_BY="[Empty name]" NAME="Counsell 2000" TYPE="COCHRANE_REVIEW">
<AU>Counsell C, Warlow C, Naylor R</AU>
<TI>Patches of different types for carotid patch angioplasty</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-09-10 14:44:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-10 14:44:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD000071. DOI: 10.1002/14651858.CD000071"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-02-01 09:50:11 +0000" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-02-01 09:50:11 +0000" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-01-12 15:46:16 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-AbuRahma-1996">
<CHAR_METHODS MODIFIED="2010-01-12 15:46:16 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: computer-generated sealed envelopes (artery randomised)<BR/>Both duplex and clinical FU blinded<BR/>Crossovers: 4 patients in vein group underwent primary closure and were excluded from the trial, 3 jugular vein patients had saphenous vein and were included in trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:40:03 +0000" MODIFIED_BY="Hazel Fraser">
<P>USA<BR/>357 patients, 399 operations in three arms: 130 vein, 134 PTFE and 135 primary closure<BR/>50% male<BR/>Mean age 68 years<BR/>33% asymptomatic<BR/>Comparability: age, sex, vascular risk factors, % asymptomatic disease similar in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-12 15:41:44 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTFE patch<BR/>Control: alternating saphenous vein patch (from ankle) and jugular vein<BR/>Routine shunting for all and GA<BR/>325 mg daily aspirin was started within 24 hours of surgery for all patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:42:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death, ipsilateral stroke, ipsilateral TIA and ipsilateral RIND at 30 days and 48 months<BR/>Duplex evidence of restenosis &gt; 50% during FU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 15:42:30 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: patients with ICA &lt; 4 mm or combined CABG or redo surgery<BR/>FU: mean 30 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-01 09:50:11 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-AbuRahma-2002">
<CHAR_METHODS MODIFIED="2010-01-12 15:46:20 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: computer-generated sealed envelopes (artery randomised)<BR/>Both duplex and clinical FU blinded<BR/>Crossovers: 4 patients in vein group underwent primary closure and were excluded from the trial, 3 jugular vein patients had saphenous vein and were included in trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:43:24 +0000" MODIFIED_BY="Hazel Fraser">
<P>USA<BR/>180 patients, 200 operations in 2 arms: 100 Dacron, 100 PTFE closure<BR/>53% male<BR/>Mean age 68 years<BR/>39% asymptomatic<BR/>Comparability: age, sex, vascular risk factors, % asymptomatic disease similar in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-01 09:50:11 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTFE patch<BR/>Control: collagen-impregnated Dacron<BR/>Routine shunting for all and GA<BR/>325 mg daily aspirin was started within 24 hours of surgery for all patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 09:51:50 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death, ipsilateral stroke, ipsilateral TIA and ipsilateral RIND at 30 days<BR/>Duplex evidence of restenosis &gt; 50% during follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 15:44:03 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: patients with ICA &lt; 4 mm or combined CABG or redo surgery<BR/>FU: mean 30 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 09:51:51 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-AbuRahma-2007">
<CHAR_METHODS MODIFIED="2010-01-12 15:46:10 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: sealed envelopes with block of 10 randomisation<BR/>Duplex and clinical FU blinded<BR/>Crossovers: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:44:34 +0000" MODIFIED_BY="Hazel Fraser">
<P>USA<BR/>200 patients, 200 operations<BR/>49.5 % male<BR/>Mean age 67.9 years<BR/>45% asymptomatic carotid disease<BR/>Comparability: age, sex, vascular risk factors, % asymptomatic disease similar in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 09:51:51 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTFE patch (ACUSEAL)<BR/>Control: Dacron patch (Hemashield-Fitnesse)<BR/>100% shunted<BR/>Postoperative aspirin 325 mg for all</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 16:23:51 +0000" MODIFIED_BY="Hazel Fraser">
<P>Perioperative outcome: neurological event, ipsilateral stroke, ipsilateral TIA, mortality, restenosis, thrombosis, combined perioperative neurological event<BR/>Long-term outcome: ipsilateral stroke, all ipsilateral TIA, all TIA and strokes, all cause mortality, stroke mortality, all TIA-stroke-death rate, &gt; 70% stenosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 15:45:34 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: concomitant CABG or redo carotid endarterectomy<BR/>FU: 30 days and long-term outcome</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-12 15:47:36 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Albrecht_x002d_Fruh-1998">
<CHAR_METHODS MODIFIED="2010-01-12 15:46:27 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: unclear<BR/>Both duplex and clinical FU: unclear<BR/>Crossovers: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:46:46 +0000" MODIFIED_BY="Hazel Fraser">
<P>Germany<BR/>52 patients, 52 operations<BR/>67% male<BR/>Mean age 67.1 years<BR/>% asymptomatic carotid disease unclear but indicated that it is similar in both groups<BR/>Comparability: age, sex, vascular risk factors, % asymptomatic disease similar in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-12 15:47:07 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: Dacron patch<BR/>Control: polyurethane patch<BR/>% shunted: unclear<BR/>Postoperative aspirin: unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:47:28 +0000" MODIFIED_BY="Hazel Fraser">
<P>Perioperative outcome: bleeding time in suture hole<BR/>Long-term outcome: stroke, restenosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 15:47:36 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: pregnancy, emergency operation, infection<BR/>FU: 30 days and long-term outcome (1 year)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 09:51:52 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Gonzalez-1994">
<CHAR_METHODS MODIFIED="2010-01-12 15:47:44 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: open random number list (artery randomised)<BR/>Clinical and DSA FU blind<BR/>Crossovers: none<BR/>Exclusions during trial: none<BR/>Patients lost to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:49:48 +0000" MODIFIED_BY="Hazel Fraser">
<P>Spain<BR/>84 patients, 95 operations<BR/>88% male<BR/>Mean age 69 years<BR/>28% asymptomatic carotid disease<BR/>Comparability: age, sex, vascular risk factors, % asymptomatic disease similar in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 09:51:52 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTFE patch<BR/>Control: saphenous vein patch (from ankle)<BR/>Routine shunting for all<BR/>Peri- and postoperative aspirin (325 mg) for all</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 15:50:38 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death &lt; 30 days, at 1 year and end of FU<BR/>Stroke &lt; 30 days, at 1 year and end of FU<BR/>Perioperative occlusion (intravenous DSA)<BR/>Perioperative wound haemorrhage, infection, cranial nerve palsy<BR/>Restenosis &gt; 50% or occlusion at 1 year and end of FU (intravenous DSA)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 15:50:51 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: none<BR/>FU: mean 29 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-12 16:23:57 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Grego-2003">
<CHAR_METHODS MODIFIED="2010-01-12 15:51:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: sealed envelopes with block randomisation<BR/>Both duplex and clinical FU blinded<BR/>Crossovers: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:51:11 +0000" MODIFIED_BY="Hazel Fraser">
<P>Italy<BR/>80 patients, 80 operations<BR/>61.9% male<BR/>Mean age 70.25 years<BR/>30.6 % asymptomatic carotid disease<BR/>Comparability: age, vascular risk factors, % asymptomatic disease similar in each group except sex</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-12 15:51:37 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTFE patch<BR/>Control: external jugular vein patch<BR/>100 % shunted<BR/>Postoperative: day 3 start aspirin, 100 mg for all</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 16:22:46 +0000" MODIFIED_BY="Hazel Fraser">
<P>Perioperative outcome: blood loss, time to haemostasis, relevant neurological complication, TIA, mortality<BR/>Long-term outcome: relevant neurological complication, stroke, mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 16:23:57 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: combined cardiac surgery, surgery to treat recurrent restenosis, lack of external jugular vein<BR/>FU: perioperative outcome and long-term (at least 3 years)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 09:51:56 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hayes-2001">
<CHAR_METHODS MODIFIED="2010-01-12 16:23:04 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: computer-generated sealed envelopes<BR/>Both duplex and clinical FU blinded<BR/>Crossovers: 3 patients randomised to vein had Dacron due to lack of vein, 6 patients had a different operation than CEA (artery randomised)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:52:49 +0000" MODIFIED_BY="Hazel Fraser">
<P>UK<BR/>274 patients, 276 operations.<BR/>67% male<BR/>Mean age 70 years<BR/>11% asymptomatic<BR/>Comparability: sex, age, vascular risk factors and % symptomatic disease was similar in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 09:51:55 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: knitted Dacron graft<BR/>Control: saphenous vein harvested from groin<BR/>Postoperative dextran given selectively according to Doppler-detected emboli<BR/>Anaesthesia and shunt use not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death, disabling stroke, non-disabling stroke and cranial nerve injury and duplex evidence of restenosis at 30 days and 3 years<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-27 09:51:56 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: 20 patients excluded prior to randomisation, 10 refusal, 6 no vein, 4 other<BR/>FU: 30 days and 3 years<BR/>2 patients refused long-term duplex follow-up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-12 16:23:09 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Katz-1996">
<CHAR_METHODS MODIFIED="2010-01-12 15:53:42 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: uncertain technique<BR/>Artery randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:54:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>USA<BR/>190 patients, 207 operations<BR/>49% male<BR/>Mean age 71 years<BR/>47% asymptomatic<BR/>Comparability: age, sex, vascular risk factors</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-12 16:23:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: knitted Dacron graft<BR/>Control: saphenous vein harvested from groin<BR/>Heparin reversed in most of Dacron patients but none of vein patients<BR/>All GA<BR/>Dextran given perioperatively<BR/>All patients shunted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death or Ipsilateral stroke &lt; 30 days<BR/>Perioperative wound haemorrhage or infection</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 15:54:29 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: 17 patients: 7 refusal, 6 absent vein graft, 4 combined CABG<BR/>FU: 30 days only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 09:51:57 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Lord-1989">
<CHAR_METHODS MODIFIED="2010-01-12 15:54:36 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: sealed envelopes (artery randomised)<BR/>Probably neither duplex nor clinical FU blind<BR/>Crossovers: 4 but not known from which group<BR/>Exclusions during trial: 4 crossovers<BR/>Patients lost to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:55:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>Australia<BR/>Number of patients unknown, 90 operations<BR/>62% male<BR/>Mean age 63 years<BR/>% asymptomatic carotid disease unknown<BR/>Comparability: age, sex, vascular risk factors, % symptomatic disease similar in each group<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 09:51:57 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTFE patch<BR/>Control: saphenous vein patch (from groin)<BR/>17% shunted<BR/>Postoperative aspirin for all</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ipsilateral stroke &lt; 30 days<BR/>Perioperative occlusion (intravenous DSA)<BR/>Perioperative wound haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 15:55:37 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: unknown<BR/>FU: until hospital discharge</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 09:52:03 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Marien-2002">
<CHAR_METHODS MODIFIED="2010-01-27 09:51:58 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: based on the last number of patient's medical record: odd number used bovine pericardium and even number used Dacron patches<BR/>Blinded duplex and clinical FU: unclear<BR/>Concealment: no<BR/>Crossovers: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 09:51:59 +0000" MODIFIED_BY="Hazel Fraser">
<P>USA<BR/>92 patients, 95 operations<BR/>61% male<BR/>Mean age 65.9 years<BR/>46.3% asymptomatic carotid disease<BR/>Comparability: age, sex, vascular risk factors, % asymptomatic disease similar in each group, but % stroke is higher in bovine patch pericardium</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 09:52:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: bovine pericardium patch<BR/>Control: Dacron patch<BR/>100 % shunted<BR/>Postoperative for all patients: continue antiplatelet</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 09:52:01 +0000" MODIFIED_BY="Hazel Fraser">
<P>Perioperative outcome: suture line blood loss, neck haematoma, TIA, stroke, death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-27 09:52:03 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: concomitant CABG and recurrent carotid stenosis<BR/>FU: perioperative</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 09:52:09 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Meerwaldt-2008">
<CHAR_METHODS MODIFIED="2010-01-12 15:57:22 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: sealed envelopes<BR/>Both duplex and clinical FU blinded<BR/>Crossovers: none<BR/>Lost to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:57:33 +0000" MODIFIED_BY="Hazel Fraser">
<P>The Netherlands<BR/>87 patients, 87 operations<BR/>79.3% male<BR/>Mean age 66.5 years<BR/>0% asymptomatic carotid disease<BR/>Comparability: age, sex, vascular risk factors similar in each group except the percentage of regressive stroke, non-regressive stroke and bilateral carotid stenosis is higher in bovine pericardium group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 09:52:07 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: polyester patch (Fluoropassiv)<BR/>Control: vein patch (ankle vein)<BR/>9.2 % shunted<BR/>Postoperative for all patients: continued Dipyridamol 150 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 09:52:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>Perioperative period: death, TIA, regressive stroke, asymptomatic recurrent stenosis/acute thrombosis, local wound complication (e.g. nerve damage, infection, pain)<BR/>At 6 weeks and 2 years: death, stroke, restenosis, acute thrombosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 15:58:48 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: known allergies to patch product, previous ipsilateral carotid surgery, bilateral carotid endarterectomy, progressive neurological events one month prior to surgery (crescendo TIA) and hospitalisation for heart failure in previous 6 months<BR/>FU: perioperative, 6 weeks and 2 years</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 09:52:12 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-O_x0027_Hara-2002">
<CHAR_METHODS MODIFIED="2010-01-27 09:52:11 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: computer-generated sealed envelopes (artery randomised)<BR/>Probably neither duplex nor clinical FU blinded<BR/>Crossovers: ? none<BR/>Exclusions during trial: 9 patients did not undergo allocated treatment<BR/>Patients lost to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 15:59:45 +0000" MODIFIED_BY="Hazel Fraser">
<P>USA<BR/>195 patients, 207 operations<BR/>74% male<BR/>Mean age 69 years<BR/>58% asymptomatic<BR/>Comparability: other than a higher incidence of males in the synthetic patch groups, age, vascular risk factors and % symptomatic disease was similar in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: knitted Dacron graft<BR/>Control: saphenous vein harvest site not specified<BR/>Anaesthesia and shunt use not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 09:52:12 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death or any stroke &lt; 30 days<BR/>Reoperation<BR/>Any hospital complication<BR/>Recurrent stenosis on follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-12 16:00:30 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: ? number excluded prior to randomisation<BR/>9 patients allocated to surgery failed to undergo it<BR/>FU: 30 days and median long-term duplex FU at 18 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 09:52:16 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Ricco-1996">
<CHAR_METHODS MODIFIED="2010-01-27 09:52:14 +0000" MODIFIED_BY="Hazel Fraser">
<P>R: opaque, sequentially numbered, sealed envelopes (artery randomised)<BR/>Follow-up blinding attempted<BR/>Crossovers: none<BR/>Exclusions during trial: none<BR/>Patients lost to FU: 3 PTFE, 4 vein patch</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-12 16:00:58 +0000" MODIFIED_BY="Hazel Fraser">
<P>France<BR/>124 patients, 141 operations<BR/>80% male<BR/>Mean age 63.5 years<BR/>33% asymptomatic carotid disease<BR/>Comparability: age, sex, vascular risk factors, % asymptomatic disease were similar in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-12 16:01:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTFE patch<BR/>Control: saphenous vein patch (90% from groin)<BR/>83% shunted<BR/>Postoperative aspirin (250 mg) for all</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-12 16:01:26 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death &lt; 30 days, 1 year and end of FU<BR/>Ipsilateral stroke &lt; 30 days, 1 year and end of FU<BR/>Perioperative occlusion (Duplex)<BR/>Perioperative wound haemorrhage<BR/>Restenosis &gt; 50% or occlusion at 1 year and end of FU (Duplex)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-27 09:52:16 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ex: external artery diameter &gt; 5 mm and internal diameter &gt; 3.5 mm, recurrent stenosis<BR/>FU: mean 53 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CABG: carotid artery bypass graft<BR/>CEA: carotid endarterectomy<BR/>DSA: digital subtraction angiography<BR/>Ex: exclusion criteria<BR/>FU: follow-up<BR/>GA: general anaesthesia<BR/>ICA: internal carotid artery<BR/>PTFE: polytetrafluoroethylene<BR/>R: concealment of allocation<BR/>RIND: reversible ischaemic neurological deficit<BR/>Rx: treatment<BR/>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-01-12 16:06:08 +0000" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-01-12 16:04:37 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Carney-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-12 16:04:37 +0000" MODIFIED_BY="Hazel Fraser">
<P>No clinical outcomes recorded (e.g. deaths, strokes, arterial complications)<BR/>74 patients randomised between Dacron, PTFE and venous patch<BR/>Randomisation by open random number list</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-12 16:05:22 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Chyatte-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-12 16:05:22 +0000" MODIFIED_BY="Hazel Fraser">
<P>No clinical outcomes recorded (e.g. deaths, strokes, arterial complications) but was looking at microemboli perioperatively</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-12 16:06:08 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Ruckert-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-12 16:06:08 +0000" MODIFIED_BY="Hazel Fraser">
<P>No clinical outcomes recorded (e.g. deaths, strokes, arterial complications) but was looking at bleeding time, microemboli perioperatively<BR/>Although there is a restenosis result, paper did not report whether that was the perioperative or long-term outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PTFE: polytetrafluoroethylene</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-09-30 20:52:38 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-01-27 09:51:54 +0000" MODIFIED_BY="Hazel Fraser">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-01-27 09:51:54 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 06:19:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AbuRahma-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 06:20:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AbuRahma-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 06:20:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AbuRahma-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:26:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albrecht_x002d_Fruh-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 09:51:54 +0000" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Gonzalez-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:26:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grego-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:25:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayes-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 14:25:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 14:55:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lord-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:25:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marien-2002">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:25:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meerwaldt-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 14:27:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Hara-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:24:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ricco-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-11-28 15:26:41 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-AbuRahma-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-AbuRahma-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:26:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AbuRahma-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:26:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albrecht_x002d_Fruh-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Gonzalez-1994">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:26:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grego-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hayes-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Katz-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lord-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:25:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marien-2002">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:25:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meerwaldt-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-O_x0027_Hara-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-28 15:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ricco-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-11-28 15:26:35 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 06:19:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AbuRahma-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 06:20:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AbuRahma-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 06:20:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AbuRahma-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 15:26:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albrecht_x002d_Fruh-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 15:26:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzalez-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 15:26:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grego-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 15:26:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayes-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 14:25:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 14:25:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lord-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 14:26:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marien-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 15:25:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meerwaldt-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 15:24:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Hara-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-28 15:25:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ricco-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-01-27 09:55:57 +0000" MODIFIED_BY="Hazel Fraser">
<COMPARISON ID="CMP-001" MODIFIED="2010-01-12 16:17:21 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<NAME>Perioperative events: synthetic versus vein (&lt; 30 days)</NAME>
<DICH_OUTCOME CHI2="1.3978024689198778" CI_END="6.382204478286852" CI_START="0.6601245930409303" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="2.0525715904525987" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.8049707143622" LOG_CI_START="-0.18037408724082094" LOG_EFFECT_SIZE="0.31229831356068954" METHOD="MH" NO="1" P_CHI2="0.8445769265213737" P_Q="0.0" P_Z="0.2140910932788126" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="406" TOTAL_2="391" WEIGHT="100.0" Z="1.242394430895167">
<NAME>Ipsilateral stroke</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3058280056677412" CI_END="6.776105165924861" CI_START="0.4879291452881853" DF="3" EFFECT_SIZE="1.8183121849651052" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.8309801376748384" LOG_CI_START="-0.31164323956392176" LOG_EFFECT_SIZE="0.2596684490554583" NO="1" P_CHI2="0.7277497509692674" P_Z="0.3730211237990484" STUDIES="4" TAU2="0.0" TOTAL_1="299" TOTAL_2="291" WEIGHT="77.41984533866454" Z="0.8908286285897072">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="28.772466820033642" CI_START="0.3033208335639715" EFFECT_SIZE="2.954198473282443" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4589770979140253" LOG_CI_START="-0.5180977591877312" LOG_EFFECT_SIZE="0.4704396693631472" ORDER="78356" O_E="0.0" SE="1.161343557739952" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="1.348718859104089" WEIGHT="22.301356860119224"/>
<DICH_DATA CI_END="69.41987770623592" CI_START="0.10953957727998762" EFFECT_SIZE="2.757575757575758" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8414838442597135" LOG_CI_START="-0.9604289393733008" LOG_EFFECT_SIZE="0.4405274524432061" ORDER="78357" O_E="0.0" SE="1.645857438797999" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="2.7088467088467088" WEIGHT="11.46746405320052"/>
<DICH_DATA CI_END="70.74767248146397" CI_START="0.11132762929594166" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8497121566333017" LOG_CI_START="-0.9533970390646103" LOG_EFFECT_SIZE="0.4481575587843459" ORDER="78358" O_E="0.0" SE="1.6465602171672553" STUDY_ID="STD-Lord-1989" TOTAL_1="47" TOTAL_2="43" VAR="2.711160548757879" WEIGHT="11.357926353087604"/>
<DICH_DATA CI_END="8.80871368219947" CI_START="0.014129925328899274" EFFECT_SIZE="0.35279805352798055" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9449124939387994" LOG_CI_START="-1.8498601332209879" LOG_EFFECT_SIZE="-0.4524738196410943" ORDER="78359" O_E="0.0" SE="1.641663275541281" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="2.695058310260928" WEIGHT="32.293098072257195"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.915564340202582" CI_START="0.29214590828326054" DF="0" EFFECT_SIZE="2.855769230769231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="1.445846411959277" LOG_CI_START="-0.5344001919224132" LOG_EFFECT_SIZE="0.455723110018432" NO="2" P_CHI2="1.0" P_Z="0.36699804467782426" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="100" WEIGHT="22.580154661335452" Z="0.9021107581327034">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="27.915564340202582" CI_START="0.29214590828326054" EFFECT_SIZE="2.855769230769231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.445846411959277" LOG_CI_START="-0.5344001919224132" LOG_EFFECT_SIZE="0.455723110018432" ORDER="78360" O_E="0.0" SE="1.1632066574988849" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="1.3530497280497282" WEIGHT="22.580154661335452"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.4802939326221125" CI_END="2.313427729536807" CI_START="0.512545154241868" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0889151355651445" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.36425593687952207" LOG_CI_START="-0.29026786807856847" LOG_EFFECT_SIZE="0.03699403440047679" METHOD="MH" MODIFIED="2010-01-12 16:17:21 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.7230889447476143" P_Q="0.0" P_Z="0.8246592123272481" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="684" TOTAL_2="685" WEIGHT="100.00000000000001" Z="0.22155641863144454">
<NAME>Any stroke</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3099533228776183" CI_END="6.921675695345875" CI_START="0.4982372719857765" DF="3" EFFECT_SIZE="1.8570505690528143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.8402112472231767" LOG_CI_START="-0.30256378701171543" LOG_EFFECT_SIZE="0.26882373010573063" MODIFIED="2009-09-15 07:52:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7267710572602064" P_Z="0.3564687605404804" STUDIES="4" TAU2="0.0" TOTAL_1="306" TOTAL_2="303" WEIGHT="26.2741418232338" Z="0.9221147004663198">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="28.772466820033642" CI_START="0.3033208335639715" EFFECT_SIZE="2.954198473282443" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4589770979140253" LOG_CI_START="-0.5180977591877312" LOG_EFFECT_SIZE="0.4704396693631472" ORDER="78361" O_E="0.0" SE="1.161343557739952" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="1.348718859104089" WEIGHT="7.646435956027344"/>
<DICH_DATA CI_END="70.13509068380634" CI_START="0.1091044322441954" EFFECT_SIZE="2.7662337662337664" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8459353628635324" LOG_CI_START="-0.9621576063310207" LOG_EFFECT_SIZE="0.4418888782662559" ORDER="78362" O_E="0.0" SE="1.649487710389259" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="39" TOTAL_2="35" VAR="2.7208097067251997" WEIGHT="3.9030923592337246"/>
<DICH_DATA CI_END="75.69322579637648" CI_START="0.12191102957439803" EFFECT_SIZE="3.0377358490566038" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8790570138343274" LOG_CI_START="-0.9139570009722064" LOG_EFFECT_SIZE="0.48255000643106066" MODIFIED="2009-09-15 07:52:42 +0100" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="1.6406302579397085" STUDY_ID="STD-Grego-2003" TOTAL_1="80" TOTAL_2="80" VAR="2.691667643267315" WEIGHT="3.7810620545919775"/>
<DICH_DATA CI_END="8.986108444624596" CI_START="0.014282819918464819" EFFECT_SIZE="0.3582554517133956" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9535716553673861" LOG_CI_START="-1.8451860394699071" LOG_EFFECT_SIZE="-0.4458071920512604" ORDER="78363" O_E="0.0" SE="1.6440041240214511" STUDY_ID="STD-Ricco-1996" TOTAL_1="53" TOTAL_2="58" VAR="2.702749559799539" WEIGHT="10.943551453380756"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9041742881189345" CI_END="3.572074852035276" CI_START="0.39153700120142065" DF="2" EFFECT_SIZE="1.1826239789691821" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.5529205508562849" LOG_CI_START="-0.40722718977902045" LOG_EFFECT_SIZE="0.07284668053863225" NO="2" P_CHI2="0.6362987466411905" P_Z="0.7661565308463787" STUDIES="3" TAU2="0.0" TOTAL_1="336" TOTAL_2="337" WEIGHT="44.67785509243174" Z="0.2974060432710955">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="7.257835620430999" CI_START="0.13986182374200648" EFFECT_SIZE="1.0075187969924813" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8608071278286904" LOG_CI_START="-0.8543008130332468" LOG_EFFECT_SIZE="0.0032531573977218607" ORDER="78364" O_E="0.0" SE="1.0074628943835329" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="1.0149814835596453" WEIGHT="15.125301219009724"/>
<DICH_DATA CI_END="27.915564340202582" CI_START="0.29214590828326054" EFFECT_SIZE="2.855769230769231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.445846411959277" LOG_CI_START="-0.5344001919224132" LOG_EFFECT_SIZE="0.455723110018432" ORDER="78365" O_E="0.0" SE="1.1632066574988849" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="1.3530497280497282" WEIGHT="7.742026979705969"/>
<DICH_DATA CI_END="4.346581181218391" CI_START="0.116023558994952" EFFECT_SIZE="0.7101449275362319" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6381477953671402" LOG_CI_START="-0.9354538167846235" LOG_EFFECT_SIZE="-0.14865301070874162" ORDER="78366" O_E="0.0" SE="0.9243413764315529" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="0.8544069801833777" WEIGHT="21.810526893716048"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.333478307323398" CI_START="0.0267840501468772" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.3680037679151811" LOG_CI_START="-1.5721237505711059" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-01-12 16:17:21 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Z="0.22382069719271147" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="29.048003084334464" Z="1.2164312791727914">
<NAME>Polyester</NAME>
<DICH_DATA CI_END="2.333478307323398" CI_START="0.0267840501468772" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3680037679151811" LOG_CI_START="-1.5721237505711059" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2009-09-15 08:10:45 +0100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="1.1396405081449492" STUDY_ID="STD-Meerwaldt-2008" TOTAL_1="42" TOTAL_2="45" VAR="1.298780487804878" WEIGHT="29.048003084334464"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.366493296730243" CI_END="1.3419980678448629" CI_START="0.19892112448829885" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5166737507526625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.12775189055360045" LOG_CI_START="-0.701319094394152" LOG_EFFECT_SIZE="-0.2867836019202758" METHOD="MH" MODIFIED="2010-01-12 16:17:18 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.9368104081107298" P_Q="0.0" P_Z="0.1751180477866233" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="684" TOTAL_2="685" WEIGHT="100.0" Z="1.3559406644916774">
<NAME>Death from all causes</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7030395115267627" CI_END="2.408397086295885" CI_START="0.16106741508094752" DF="3" EFFECT_SIZE="0.6228276592912071" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.38172809312139816" LOG_CI_START="-0.7929923111133925" LOG_EFFECT_SIZE="-0.20563210899599713" MODIFIED="2009-09-15 07:59:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6362583431303335" P_Z="0.4926031506994606" STUDIES="4" TAU2="0.0" TOTAL_1="306" TOTAL_2="303" WEIGHT="44.19912212902832" Z="0.6861743888065055">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="4.018467712337914" CI_START="0.00908575861980479" EFFECT_SIZE="0.19107806691449813" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6040604832002069" LOG_CI_START="-2.0416388052144714" LOG_EFFECT_SIZE="-0.7187891610071322" ORDER="78367" O_E="0.0" SE="1.5540968584374761" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="2.415217045405233" WEIGHT="20.456750712821247"/>
<DICH_DATA CI_END="70.13509068380634" CI_START="0.1091044322441954" EFFECT_SIZE="2.7662337662337664" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8459353628635324" LOG_CI_START="-0.9621576063310207" LOG_EFFECT_SIZE="0.4418888782662559" ORDER="78368" O_E="0.0" SE="1.649487710389259" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="39" TOTAL_2="35" VAR="2.7208097067251997" WEIGHT="4.09895488260619"/>
<DICH_DATA CI_END="8.202703262297813" CI_START="0.013211221869313847" EFFECT_SIZE="0.32919254658385094" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9139570009722063" LOG_CI_START="-1.8790570138343274" LOG_EFFECT_SIZE="-0.4825500064310606" MODIFIED="2009-09-15 07:59:00 +0100" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="1.6406302579397085" STUDY_ID="STD-Grego-2003" TOTAL_1="80" TOTAL_2="80" VAR="2.691667643267315" WEIGHT="12.06224433467276"/>
<DICH_DATA CI_END="17.97500480424112" CI_START="0.06684578210262111" EFFECT_SIZE="1.0961538461538463" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.25466901513031" LOG_CI_START="-1.1749259910549255" LOG_EFFECT_SIZE="0.03987151203769228" ORDER="78369" O_E="0.0" SE="1.4271561333224518" STUDY_ID="STD-Ricco-1996" TOTAL_1="53" TOTAL_2="58" VAR="2.036774628879892" WEIGHT="7.581172198928121"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4976191283587309" CI_END="2.0341769915685424" CI_START="0.1015511531604356" DF="2" EFFECT_SIZE="0.4545030464432678" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.308388737730005" LOG_CI_START="-0.9933151406159401" LOG_EFFECT_SIZE="-0.3424632014429675" NO="2" P_CHI2="0.7797284568980503" P_Z="0.30240598133826113" STUDIES="3" TAU2="0.0" TOTAL_1="336" TOTAL_2="337" WEIGHT="44.209203330637834" Z="1.0312876100690505">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="3.2211795619859602" CI_START="0.03398100670195717" EFFECT_SIZE="0.3308457711442786" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5080149348805666" LOG_CI_START="-1.468763759115335" LOG_EFFECT_SIZE="-0.4803744121173843" ORDER="78370" O_E="0.0" SE="1.1611695900655419" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="1.3483148168929786" WEIGHT="24.005610691212787"/>
<DICH_DATA CI_END="7.661862105443698" CI_START="0.012423741087506653" EFFECT_SIZE="0.3085271317829457" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8843343314915133" LOG_CI_START="-1.9057476079426359" LOG_EFFECT_SIZE="-0.5107066382255612" ORDER="78371" O_E="0.0" SE="1.6389079423519624" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="2.6860192435043433" WEIGHT="12.485600468859468"/>
<DICH_DATA CI_END="17.439222642388337" CI_START="0.0662990004176925" EFFECT_SIZE="1.075268817204301" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2415271222453186" LOG_CI_START="-1.1784930193531888" LOG_EFFECT_SIZE="0.031517051446064856" ORDER="78372" O_E="0.0" SE="1.4215318104678638" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="2.020752688172043" WEIGHT="7.717992170565582"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.806310843010866" CI_START="0.013832658059720393" DF="0" EFFECT_SIZE="0.34901960784313724" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.9447940110146922" LOG_CI_START="-1.8590943585927768" LOG_EFFECT_SIZE="-0.45715017378904244" MODIFIED="2010-01-12 16:17:18 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Z="0.5227507624769836" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="11.591674540333862" Z="0.6391109474006523">
<NAME>Polyester</NAME>
<DICH_DATA CI_END="8.80631084301086" CI_START="0.013832658059720393" EFFECT_SIZE="0.34901960784313724" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9447940110146917" LOG_CI_START="-1.8590943585927768" LOG_EFFECT_SIZE="-0.45715017378904244" MODIFIED="2009-09-15 08:12:16 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.6470179077787017" STUDY_ID="STD-Meerwaldt-2008" TOTAL_1="42" TOTAL_2="45" VAR="2.712667988543732" WEIGHT="11.591674540333862"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07513725951526612" CI_END="1.6634173966279695" CI_START="0.04426909886348015" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.27136320528501345" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.22100123918176948" LOG_CI_START="-1.3538993183780803" LOG_EFFECT_SIZE="-0.5664490395981554" METHOD="MH" MODIFIED="2010-01-12 16:16:19 +0000" MODIFIED_BY="Hazel Fraser" NO="4" P_CHI2="0.9631283167941147" P_Q="0.0" P_Z="0.15857162466925145" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="562" TOTAL_2="560" WEIGHT="100.00000000000001" Z="1.409891832675279">
<NAME>Fatal stroke</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.986108444624605" CI_START="0.014282819918464819" DF="0" EFFECT_SIZE="0.3582554517133956" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.9535716553673864" LOG_CI_START="-1.8451860394699071" LOG_EFFECT_SIZE="-0.4458071920512604" NO="1" P_CHI2="1.0" P_Z="0.5323677962297875" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="223" WEIGHT="26.084987941923846" Z="0.6243956324487734">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78373" O_E="0.0" SE="0.0" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78374" O_E="0.0" SE="0.0" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="39" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.986108444624596" CI_START="0.014282819918464819" EFFECT_SIZE="0.3582554517133956" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9535716553673861" LOG_CI_START="-1.8451860394699071" LOG_EFFECT_SIZE="-0.4458071920512604" ORDER="78375" O_E="0.0" SE="1.6440041240214511" STUDY_ID="STD-Ricco-1996" TOTAL_1="53" TOTAL_2="58" VAR="2.702749559799539" WEIGHT="26.084987941923846"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03831366707931761" CI_END="2.174532537154093" CI_START="0.02664285748381131" DF="1" EFFECT_SIZE="0.2406984845845672" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.33736591032315805" LOG_CI_START="-1.5744191983117939" LOG_EFFECT_SIZE="-0.6185266439943179" NO="2" P_CHI2="0.8448147176896463" P_Z="0.20471647491566514" STUDIES="3" TAU2="0.0" TOTAL_1="336" TOTAL_2="337" WEIGHT="73.91501205807617" Z="1.268228254558262">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="4.174000783855362" CI_START="0.00944220539391227" EFFECT_SIZE="0.1985239852398524" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6205525262876591" LOG_CI_START="-2.0249265567036923" LOG_EFFECT_SIZE="-0.7021870152080165" ORDER="78376" O_E="0.0" SE="1.5539675086817792" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="2.414815018038656" WEIGHT="45.57647152017698"/>
<DICH_DATA CI_END="7.661862105443698" CI_START="0.012423741087506653" EFFECT_SIZE="0.3085271317829457" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8843343314915133" LOG_CI_START="-1.9057476079426359" LOG_EFFECT_SIZE="-0.5107066382255612" ORDER="78377" O_E="0.0" SE="1.6389079423519624" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="2.6860192435043433" WEIGHT="28.338540537899195"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78378" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7267858854572553" CI_END="2.658562451050214" CI_START="0.5847949311494998" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2468816485611436" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.4246468665790812" LOG_CI_START="-0.23299640038559655" LOG_EFFECT_SIZE="0.0958252330967423" METHOD="MH" NO="5" P_CHI2="0.8855080716366004" P_Q="0.0" P_Z="0.5678824496850314" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="562" TOTAL_2="560" WEIGHT="100.0" Z="0.5711728990904672">
<NAME>Stroke or death</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8363057331480348" CI_END="4.798090823597745" CI_START="0.4189195642532011" DF="2" EFFECT_SIZE="1.4177496665733518" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.681068464518432" LOG_CI_START="-0.37786935687726037" LOG_EFFECT_SIZE="0.1515995538205858" NO="1" P_CHI2="0.6582616105384467" P_Z="0.5746718743709592" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="223" WEIGHT="36.52237005548991" Z="0.5611843482350445">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="4.892969191456065" CI_START="0.19208452118417782" EFFECT_SIZE="0.9694656488549618" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6895724812365887" LOG_CI_START="-0.7165076306362035" LOG_EFFECT_SIZE="-0.013467574699807418" ORDER="78379" O_E="0.0" SE="0.8259384179228847" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.6821742702009577" WEIGHT="24.670182982003386"/>
<DICH_DATA CI_END="102.05221917046256" CI_START="0.219539022537288" EFFECT_SIZE="4.733333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.008822453079599" LOG_CI_START="-0.6584882737528113" LOG_EFFECT_SIZE="0.675167089663394" ORDER="78380" O_E="0.0" SE="1.5667915243423975" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="39" TOTAL_2="35" VAR="2.4548356807511738" WEIGHT="4.088569899588749"/>
<DICH_DATA CI_END="17.97500480424112" CI_START="0.06684578210262111" EFFECT_SIZE="1.0961538461538463" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.25466901513031" LOG_CI_START="-1.1749259910549255" LOG_EFFECT_SIZE="0.03987151203769228" ORDER="78381" O_E="0.0" SE="1.4271561333224518" STUDY_ID="STD-Ricco-1996" TOTAL_1="53" TOTAL_2="58" VAR="2.036774628879892" WEIGHT="7.763617173897772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8554444501410183" CI_END="3.024527808769436" CI_START="0.4361725932210463" DF="2" EFFECT_SIZE="1.148571346334277" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.4806575819462272" LOG_CI_START="-0.3603416266683849" LOG_EFFECT_SIZE="0.060157977638921195" NO="2" P_CHI2="0.6519925158306434" P_Z="0.7791717675374633" STUDIES="3" TAU2="0.0" TOTAL_1="336" TOTAL_2="337" WEIGHT="63.4776299445101" Z="0.2803985267697977">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="5.0828218943487204" CI_START="0.19973332301553015" EFFECT_SIZE="1.0075757575757576" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7061048919854628" LOG_CI_START="-0.6995494724629909" LOG_EFFECT_SIZE="0.003277709761235921" ORDER="78382" O_E="0.0" SE="0.8256883317783444" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="0.6817612212349053" WEIGHT="24.216403384604774"/>
<DICH_DATA CI_END="27.915564340202582" CI_START="0.29214590828326054" EFFECT_SIZE="2.855769230769231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.445846411959277" LOG_CI_START="-0.5344001919224132" LOG_EFFECT_SIZE="0.455723110018432" ORDER="78383" O_E="0.0" SE="1.1632066574988849" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="1.3530497280497282" WEIGHT="8.326198128528045"/>
<DICH_DATA CI_END="3.6700284439223965" CI_START="0.17414611106766117" EFFECT_SIZE="0.7994505494505495" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5646694301896016" LOG_CI_START="-0.7590862195158992" LOG_EFFECT_SIZE="-0.09720839466314866" ORDER="78384" O_E="0.0" SE="0.7775806213331578" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="0.6046316226728597" WEIGHT="30.935028431377276"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1162092644587418" CI_END="3.5396226826350587" CI_START="0.1324902203321109" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.684810476785261" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.5489569694881707" LOG_CI_START="-0.8778161776709413" LOG_EFFECT_SIZE="-0.16442960409138524" METHOD="MH" NO="6" P_CHI2="0.5722928841354615" P_Q="0.0" P_Z="0.6514453405762255" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="541" TOTAL_2="527" WEIGHT="100.0" Z="0.45175521091490684">
<NAME>Arterial rupture</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7823986415784405" CI_END="7.225652800435634" CI_START="0.13372232138892123" DF="1" EFFECT_SIZE="0.9829705316155782" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.8588770894659375" LOG_CI_START="-0.8737960927611321" LOG_EFFECT_SIZE="-0.007459501647597288" NO="1" P_CHI2="0.3764085966826828" P_Z="0.9865354856159345" STUDIES="4" TAU2="0.0" TOTAL_1="299" TOTAL_2="291" WEIGHT="55.791686166058184" Z="0.016876067249007445">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78385" O_E="0.0" SE="0.0" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="69.41987770623592" CI_START="0.10953957727998762" EFFECT_SIZE="2.757575757575758" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8414838442597135" LOG_CI_START="-0.9604289393733008" LOG_EFFECT_SIZE="0.4405274524432061" ORDER="78386" O_E="0.0" SE="1.645857438797999" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="2.7088467088467088" WEIGHT="14.62022251319572"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78387" O_E="0.0" SE="0.0" STUDY_ID="STD-Lord-1989" TOTAL_1="47" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.80871368219947" CI_START="0.014129925328899274" EFFECT_SIZE="0.35279805352798055" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9449124939387994" LOG_CI_START="-1.8498601332209879" LOG_EFFECT_SIZE="-0.4524738196410943" ORDER="78388" O_E="0.0" SE="1.641663275541281" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="2.695058310260928" WEIGHT="41.171463652862464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.661862105443702" CI_START="0.012423741087506653" DF="0" EFFECT_SIZE="0.3085271317829457" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.8843343314915135" LOG_CI_START="-1.9057476079426359" LOG_EFFECT_SIZE="-0.5107066382255612" NO="2" P_CHI2="1.0" P_Z="0.47305471116365905" STUDIES="2" TAU2="0.0" TOTAL_1="242" TOTAL_2="236" WEIGHT="44.20831383394182" Z="0.7175177212111776">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78389" O_E="0.0" SE="0.0" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.661862105443698" CI_START="0.012423741087506653" EFFECT_SIZE="0.3085271317829457" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8843343314915133" LOG_CI_START="-1.9057476079426359" LOG_EFFECT_SIZE="-0.5107066382255612" ORDER="78390" O_E="0.0" SE="1.6389079423519624" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="2.6860192435043433" WEIGHT="44.20831383394182"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.29200298887828113" CI_END="2.706760690394712" CI_START="0.5262302704485564" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1934736738386527" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.4324498607076086" LOG_CI_START="-0.2788241735238673" LOG_EFFECT_SIZE="0.07681284359187068" METHOD="MH" MODIFIED="2010-01-12 16:17:12 +0000" MODIFIED_BY="Hazel Fraser" NO="7" P_CHI2="0.961525420149818" P_Q="0.0" P_Z="0.6720574055641846" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="361" TOTAL_2="356" WEIGHT="100.0" Z="0.42332603116277956">
<NAME>Cranial nerve palsy</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08300523096722694" CI_END="5.756959119932691" CI_START="0.28083028184192316" DF="1" EFFECT_SIZE="1.2715063712790144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.7601931455484661" LOG_CI_START="-0.5515560641783551" LOG_EFFECT_SIZE="0.10431854068505537" NO="1" P_CHI2="0.7732653935907596" P_Z="0.755240173812202" STUDIES="2" TAU2="0.0" TOTAL_1="184" TOTAL_2="175" WEIGHT="28.66860999723479" Z="0.31173730640945446">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="8.91733994778508" CI_START="0.24089320118209553" EFFECT_SIZE="1.465648854961832" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9502353231780342" LOG_CI_START="-0.6181754570824636" LOG_EFFECT_SIZE="0.16602993304778535" ORDER="78391" O_E="0.0" SE="0.921292256083591" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.8487794211195929" WEIGHT="18.864318268682226"/>
<DICH_DATA CI_END="14.789364584779722" CI_START="0.05452098302947701" EFFECT_SIZE="0.8979591836734694" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1699495152239403" LOG_CI_START="-1.263436322308593" LOG_EFFECT_SIZE="-0.04674340354232623" ORDER="78392" O_E="0.0" SE="1.4293828864207725" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="2.043135435992579" WEIGHT="9.804291728552563"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.206646539641006" CI_START="0.31670592812677234" DF="0" EFFECT_SIZE="1.0077519379844961" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.5060510914084997" LOG_CI_START="-0.49934380739332407" LOG_EFFECT_SIZE="0.003353642007587811" NO="2" P_CHI2="1.0" P_Z="0.9895675623734318" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="136" WEIGHT="54.28944730781459" Z="0.013075494136176912">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="3.206646539641006" CI_START="0.31670592812677234" EFFECT_SIZE="1.0077519379844961" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5060510914084997" LOG_CI_START="-0.49934380739332407" LOG_EFFECT_SIZE="0.003353642007587811" ORDER="78393" O_E="0.0" SE="0.5905739403412049" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="0.34877757901013706" WEIGHT="54.28944730781459"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.423272826888173" CI_START="0.2624134613013196" DF="0" EFFECT_SIZE="1.6538461538461537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="1.0180041054783533" LOG_CI_START="-0.5810138902608163" LOG_EFFECT_SIZE="0.2184951076087685" MODIFIED="2010-01-12 16:17:12 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Z="0.5922129640533023" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="17.04194269495062" Z="0.5356319226581667">
<NAME>Polyester</NAME>
<DICH_DATA CI_END="10.423272826888173" CI_START="0.2624134613013195" EFFECT_SIZE="1.6538461538461537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0180041054783533" LOG_CI_START="-0.5810138902608165" LOG_EFFECT_SIZE="0.2184951076087685" MODIFIED="2009-09-15 08:09:55 +0100" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.9392710859639232" STUDY_ID="STD-Meerwaldt-2008" TOTAL_1="42" TOTAL_2="45" VAR="0.8822301729278474" WEIGHT="17.04194269495062"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4242652430139805" CI_END="1.2341034859697984" CI_START="0.11769296248177476" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.38111060766248805" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.09135157906611859" LOG_CI_START="-0.9292495052679328" LOG_EFFECT_SIZE="-0.4189489631009071" METHOD="MH" NO="8" P_CHI2="0.5148164260405987" P_Q="0.0" P_Z="0.10759435874333603" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="336" TOTAL_2="337" WEIGHT="100.0" Z="1.6091005421064535">
<NAME>Wound infection</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>PTFE</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4242652430139805" CI_END="1.2341034859697984" CI_START="0.11769296248177476" DF="1" EFFECT_SIZE="0.38111060766248805" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.09135157906611859" LOG_CI_START="-0.9292495052679328" LOG_EFFECT_SIZE="-0.4189489631009071" NO="2" P_CHI2="0.5148164260405987" P_Z="0.10759435874333603" STUDIES="3" TAU2="0.0" TOTAL_1="336" TOTAL_2="337" WEIGHT="100.0" Z="1.6091005421064535">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="1.358964046558917" CI_START="0.056510881654252935" EFFECT_SIZE="0.2771213748657358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.1332079669697151" LOG_CI_START="-1.2478679170059401" LOG_EFFECT_SIZE="-0.5573299750181124" ORDER="78394" O_E="0.0" SE="0.8112508106831822" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="0.6581278778341202" WEIGHT="69.30222020842773"/>
<DICH_DATA CI_END="3.764615064163732" CI_START="0.10075387927205813" EFFECT_SIZE="0.6158730158730159" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5757205757409101" LOG_CI_START="-0.996738223459659" LOG_EFFECT_SIZE="-0.21050882385937442" ORDER="78395" O_E="0.0" SE="0.9236700824470057" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="0.8531664212076582" WEIGHT="30.69777979157227"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78396" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.028719036641138" CI_END="3.4650116398435187" CI_START="0.8517371374655247" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.717928722446028" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.5397046978544113" LOG_CI_START="-0.06969441622198723" LOG_EFFECT_SIZE="0.23500514081621202" METHOD="MH" NO="9" P_CHI2="0.84515715044044" P_Q="0.0" P_Z="0.13062081394753583" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="635" TOTAL_2="628" WEIGHT="100.0" Z="1.5116582927089564">
<NAME>Complication requiring further operation</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7956359343951763" CI_END="4.973604503430544" CI_START="0.19466172022993686" DF="2" EFFECT_SIZE="0.9839565073625718" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.6966712475992319" LOG_CI_START="-0.7107194430737188" LOG_EFFECT_SIZE="-0.007024097737243409" NO="1" P_CHI2="0.6717845244239845" P_Z="0.9843913149719749" STUDIES="4" TAU2="0.0" TOTAL_1="299" TOTAL_2="291" WEIGHT="24.016368906319915" Z="0.01956383352557721">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="15.671326225090796" CI_START="0.06003028253507791" EFFECT_SIZE="0.9699248120300752" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1951057512781922" LOG_CI_START="-1.221629612613866" LOG_EFFECT_SIZE="-0.013261930667836827" ORDER="78397" O_E="0.0" SE="1.4196023157831834" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="2.015270734976977" WEIGHT="8.202613013416448"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78398" O_E="0.0" SE="0.0" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.74767248146397" CI_START="0.11132762929594166" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8497121566333017" LOG_CI_START="-0.9533970390646103" LOG_EFFECT_SIZE="0.4481575587843459" ORDER="78399" O_E="0.0" SE="1.6465602171672553" STUDY_ID="STD-Lord-1989" TOTAL_1="47" TOTAL_2="43" VAR="2.711160548757879" WEIGHT="4.11471385063339"/>
<DICH_DATA CI_END="8.80871368219947" CI_START="0.014129925328899274" EFFECT_SIZE="0.35279805352798055" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9449124939387994" LOG_CI_START="-1.8498601332209879" LOG_EFFECT_SIZE="-0.4524738196410943" ORDER="78400" O_E="0.0" SE="1.641663275541281" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="2.695058310260928" WEIGHT="11.699042042270076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7911535775609064" CI_END="4.278987604485522" CI_START="0.8885695624688832" DF="2" EFFECT_SIZE="1.949917470952931" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.6313410284069673" LOG_CI_START="-0.05130856739292751" LOG_EFFECT_SIZE="0.29001623050701986" NO="2" P_CHI2="0.6732917931539568" P_Z="0.09584521835059365" STUDIES="3" TAU2="0.0" TOTAL_1="336" TOTAL_2="337" WEIGHT="75.98363109368009" Z="1.665338616540973">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="3.9943716193313197" CI_START="0.5441452559966861" EFFECT_SIZE="1.4742857142857142" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6014484673241443" LOG_CI_START="-0.26428515277027287" LOG_EFFECT_SIZE="0.1685816572769357" ORDER="78401" O_E="0.0" SE="0.508536213893995" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="0.258609080841639" WEIGHT="52.57064079291955"/>
<DICH_DATA CI_END="16.920585105835592" CI_START="0.6953010150897506" EFFECT_SIZE="3.43" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2284153766605819" LOG_CI_START="-0.1578271365750408" LOG_EFFECT_SIZE="0.5352941200427705" ORDER="78402" O_E="0.0" SE="0.8142857142857143" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="0.6630612244897959" WEIGHT="15.731283538861225"/>
<DICH_DATA CI_END="24.376651504279252" CI_START="0.19386985615211738" EFFECT_SIZE="2.1739130434782608" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3869740485715383" LOG_CI_START="-0.7124897119346866" LOG_EFFECT_SIZE="0.3372421683184259" ORDER="78403" O_E="0.0" SE="1.2332354054345793" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="1.5208695652173914" WEIGHT="7.681706761899313"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.812580195518894" CI_END="7.783086700670891" CI_START="0.5978029582111317" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="2.157023934423254" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.891151868353592" LOG_CI_START="-0.223441940197387" LOG_EFFECT_SIZE="0.3338549640781024" METHOD="MH" MODIFIED="2009-09-15 08:11:42 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9367536137879912" P_Q="0.0" P_Z="0.24033960803603782" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="583" TOTAL_2="572" WEIGHT="100.0" Z="1.1741384181985899">
<NAME>Arterial occlusion</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5469056837067345" CI_END="13.122429844532027" CI_START="0.4778427638602651" DF="2" EFFECT_SIZE="2.5040882862777845" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="1.118014259610187" LOG_CI_START="-0.3207149862783323" LOG_EFFECT_SIZE="0.3986496366659273" NO="1" P_CHI2="0.7607482288518612" P_Z="0.2774120083346986" STUDIES="4" TAU2="0.0" TOTAL_1="299" TOTAL_2="291" WEIGHT="57.36656531803371" Z="1.0861514528157972">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="103.56484365687278" CI_START="0.2341622710929923" EFFECT_SIZE="4.9245283018867925" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0152123538935793" LOG_CI_START="-0.6304830784185959" LOG_EFFECT_SIZE="0.6923646377374919" ORDER="78404" O_E="0.0" SE="1.554094593343778" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="2.415210005060363" WEIGHT="14.624755108927744"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78405" O_E="0.0" SE="0.0" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.74767248146397" CI_START="0.11132762929594166" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8497121566333017" LOG_CI_START="-0.9533970390646103" LOG_EFFECT_SIZE="0.4481575587843459" ORDER="78406" O_E="0.0" SE="1.6465602171672553" STUDY_ID="STD-Lord-1989" TOTAL_1="47" TOTAL_2="43" VAR="2.711160548757879" WEIGHT="14.839507460404207"/>
<DICH_DATA CI_END="17.525844907248064" CI_START="0.06589256646597752" EFFECT_SIZE="1.0746268656716418" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2436789641400088" LOG_CI_START="-1.1811635766791249" LOG_EFFECT_SIZE="0.03125769373044202" ORDER="78407" O_E="0.0" SE="1.4243645116413206" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="2.0288142620232175" WEIGHT="27.902302748701754"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.30324829471799" CI_START="0.11399873331772702" DF="0" EFFECT_SIZE="2.8309859154929575" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="1.846975391646861" LOG_CI_START="-0.9430999742440338" LOG_EFFECT_SIZE="0.45193770870141353" NO="2" P_CHI2="1.0" P_Z="0.5254598812187157" STUDIES="2" TAU2="0.0" TOTAL_1="242" TOTAL_2="236" WEIGHT="14.960898708343924" Z="0.6349517601847915">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78408" O_E="0.0" SE="0.0" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.30324829471799" CI_START="0.11399873331772702" EFFECT_SIZE="2.8309859154929575" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.846975391646861" LOG_CI_START="-0.9430999742440338" LOG_EFFECT_SIZE="0.45193770870141353" ORDER="78409" O_E="0.0" SE="1.6389040810201152" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="2.686006586784388" WEIGHT="14.960898708343924"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.723391524104905" CI_START="0.06498166097763185" DF="0" EFFECT_SIZE="1.0731707317073171" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="1.248546831505152" LOG_CI_START="-1.187209191972248" LOG_EFFECT_SIZE="0.03066881976645196" MODIFIED="2009-09-15 08:11:42 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9606354646838248" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="27.672535973622377" Z="0.04935616015004689">
<NAME>Polyester</NAME>
<DICH_DATA CI_END="17.723391524104912" CI_START="0.06498166097763182" EFFECT_SIZE="1.0731707317073171" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2485468315051522" LOG_CI_START="-1.1872091919722483" LOG_EFFECT_SIZE="0.03066881976645196" MODIFIED="2009-09-15 08:11:42 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="1.4307751453773971" STUDY_ID="STD-Meerwaldt-2008" TOTAL_1="42" TOTAL_2="45" VAR="2.047117516629712" WEIGHT="27.672535973622377"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8739951635093237" CI_END="3.2793459346752822" CI_START="0.8113613574031887" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6311758240461895" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.5157872323436861" LOG_CI_START="-0.09078568022326099" LOG_EFFECT_SIZE="0.21250077606021256" METHOD="MH" MODIFIED="2009-09-15 08:09:03 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.7589204130616536" P_Q="0.0" P_Z="0.16966875734118916" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="677" TOTAL_2="673" WEIGHT="99.99999999999999" Z="1.373268931519786">
<NAME>Wound haemorrhage</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.671326225090796" CI_START="0.06003028253507791" DF="0" EFFECT_SIZE="0.9699248120300752" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="1.1951057512781922" LOG_CI_START="-1.221629612613866" LOG_EFFECT_SIZE="-0.013261930667836827" NO="1" P_CHI2="1.0" P_Z="0.9828382206869882" STUDIES="4" TAU2="0.0" TOTAL_1="299" TOTAL_2="291" WEIGHT="7.977829868539391" Z="0.021510759401117754">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="15.671326225090796" CI_START="0.06003028253507791" EFFECT_SIZE="0.9699248120300752" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1951057512781922" LOG_CI_START="-1.221629612613866" LOG_EFFECT_SIZE="-0.013261930667836827" ORDER="78410" O_E="0.0" SE="1.4196023157831834" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="2.015270734976977" WEIGHT="7.977829868539391"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78411" O_E="0.0" SE="0.0" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78412" O_E="0.0" SE="0.0" STUDY_ID="STD-Lord-1989" TOTAL_1="47" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78413" O_E="0.0" SE="0.0" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7357139504582157" CI_END="3.7195608710295454" CI_START="0.7722503661627791" DF="2" EFFECT_SIZE="1.6948251368850156" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.5704916703803127" LOG_CI_START="-0.11224187710558364" LOG_EFFECT_SIZE="0.22912489663736452" NO="2" P_CHI2="0.4198506890589815" P_Z="0.1883335009787168" STUDIES="3" TAU2="0.0" TOTAL_1="336" TOTAL_2="337" WEIGHT="77.82465283365029" Z="1.3155250595913448">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="3.9943716193313197" CI_START="0.5441452559966861" EFFECT_SIZE="1.4742857142857142" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6014484673241443" LOG_CI_START="-0.26428515277027287" LOG_EFFECT_SIZE="0.1685816572769357" ORDER="78414" O_E="0.0" SE="0.508536213893995" STUDY_ID="STD-Hayes-2001" TOTAL_1="135" TOTAL_2="136" VAR="0.258609080841639" WEIGHT="51.13000304171682"/>
<DICH_DATA CI_END="16.920585105835592" CI_START="0.6953010150897506" EFFECT_SIZE="3.43" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2284153766605819" LOG_CI_START="-0.1578271365750408" LOG_EFFECT_SIZE="0.5352941200427705" ORDER="78415" O_E="0.0" SE="0.8142857142857143" STUDY_ID="STD-Katz-1996" TOTAL_1="107" TOTAL_2="100" VAR="0.6630612244897959" WEIGHT="15.300185865347421"/>
<DICH_DATA CI_END="8.809682994763572" CI_START="0.01426480094917373" EFFECT_SIZE="0.3544973544973545" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9449602811587119" LOG_CI_START="-1.8457342841035471" LOG_EFFECT_SIZE="-0.4503870014724177" ORDER="78416" O_E="0.0" SE="1.639267801795941" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="2.6871989260048963" WEIGHT="11.39446392658605"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.423272826888173" CI_START="0.2624134613013196" DF="0" EFFECT_SIZE="1.6538461538461537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="1.0180041054783533" LOG_CI_START="-0.5810138902608163" LOG_EFFECT_SIZE="0.2184951076087685" MODIFIED="2009-09-15 08:09:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5922129640533023" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="14.197517297810315" Z="0.5356319226581667">
<NAME>Polyester</NAME>
<DICH_DATA CI_END="10.423272826888173" CI_START="0.2624134613013195" EFFECT_SIZE="1.6538461538461537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0180041054783533" LOG_CI_START="-0.5810138902608165" LOG_EFFECT_SIZE="0.2184951076087685" MODIFIED="2009-09-15 08:09:03 +0100" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.9392710859639232" STUDY_ID="STD-Meerwaldt-2008" TOTAL_1="42" TOTAL_2="45" VAR="0.8822301729278474" WEIGHT="14.197517297810315"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-01-12 16:17:54 +0000" MODIFIED_BY="Hazel Fraser" NO="2">
<NAME>Perioperative events: Dacron versus other synthetic patch (&lt; 30 days)</NAME>
<DICH_OUTCOME CHI2="2.7466233238056783" CI_END="15.732078439603251" CI_START="0.9614345572646998" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="3.889134077070818" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="63.591658479968935" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.1967861031204912" LOG_CI_START="-0.01708027188945484" LOG_EFFECT_SIZE="0.5898529156155182" METHOD="MH" MODIFIED="2009-10-01 12:30:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09746013432842981" P_Q="0.0" P_Z="0.056805187911965295" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="200" WEIGHT="99.99999999999999" Z="1.9048068133082388">
<NAME>Ipsilateral Stroke</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dacron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTFE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7466233238056783" CI_END="15.732078439603251" CI_START="0.9614345572646998" DF="1" EFFECT_SIZE="3.889134077070818" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="63.591658479968935" ID="CMP-002.01.01" LOG_CI_END="1.1967861031204912" LOG_CI_START="-0.01708027188945484" LOG_EFFECT_SIZE="0.5898529156155182" MODIFIED="2009-09-20 10:53:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09746013432842981" P_Z="0.056805187911965295" STUDIES="2" TAU2="0.0" TOTAL_1="200" TOTAL_2="200" WEIGHT="99.99999999999999" Z="1.9048068133082388">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="286.2243030867659" CI_START="0.9082071429927607" EFFECT_SIZE="16.122994652406415" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4567065066018405" LOG_CI_START="-0.04181508672249867" LOG_EFFECT_SIZE="1.2074457099396712" ORDER="78417" O_E="0.0" SE="1.4676439518000706" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="2.153978769255328" WEIGHT="19.104245842017082"/>
<DICH_DATA CI_END="7.24174794563768" CI_START="0.138088208469391" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8598434048052552" LOG_CI_START="-0.8598434048052552" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-15 11:46:09 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="1.0101525445522106" STUDY_ID="STD-AbuRahma-2007" TOTAL_1="100" TOTAL_2="100" VAR="1.020408163265306" WEIGHT="80.8957541579829"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9974758446523677" CI_END="20.899290719790223" CI_START="0.901602290471323" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="4.340834986749545" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="66.63859687863557" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.320131547273339" LOG_CI_START="-0.04498499365916261" LOG_EFFECT_SIZE="0.6375732768070882" METHOD="MH" MODIFIED="2010-01-12 16:17:44 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.08339454528235746" P_Q="0.0" P_Z="0.06713193637196403" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="151" WEIGHT="100.0" Z="1.8307897129331865">
<NAME>Any stroke</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dacron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTFE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="286.2243030867659" CI_START="0.9082071429927612" DF="0" EFFECT_SIZE="16.122994652406415" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="2.4567065066018405" LOG_CI_START="-0.041815086722498465" LOG_EFFECT_SIZE="1.2074457099396712" MODIFIED="2009-09-20 10:54:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05817719716960129" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="25.167538467942226" Z="1.894360337803128">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="286.2243030867659" CI_START="0.9082071429927607" EFFECT_SIZE="16.122994652406415" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4567065066018405" LOG_CI_START="-0.04181508672249867" LOG_EFFECT_SIZE="1.2074457099396712" ORDER="78418" O_E="0.0" SE="1.4676439518000706" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="2.153978769255328" WEIGHT="25.167538467942226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.550100448801673E-33" CI_END="9.523372507497491" CI_START="0.01502551798654611" DF="0" EFFECT_SIZE="0.37827715355805236" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-002.02.02" LOG_CI_END="0.978790772126679" LOG_CI_START="-1.8231705472905446" LOG_EFFECT_SIZE="-0.4221898875819327" MODIFIED="2009-09-20 12:36:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.5547608199707743" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="51" WEIGHT="74.83246153205778" Z="0.5906412544408061">
<NAME>Bovine pericardium</NAME>
<DICH_DATA CI_END="9.523372507497491" CI_START="0.01502551798654611" EFFECT_SIZE="0.3782771535580524" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.978790772126679" LOG_CI_START="-1.8231705472905446" LOG_EFFECT_SIZE="-0.42218988758193265" MODIFIED="2009-09-20 12:36:38 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="1.6458859489578996" STUDY_ID="STD-Marien-2002" TOTAL_1="44" TOTAL_2="51" VAR="2.708940556977046" WEIGHT="74.83246153205778"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.14008884852644" CI_START="1.2044594566406577" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.409090909090909" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.2079059211121081" LOG_CI_START="0.080792185775969" LOG_EFFECT_SIZE="0.6443490534440386" METHOD="MH" MODIFIED="2010-01-12 16:17:54 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.02502952366986071" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="2.2409467627437887">
<NAME>Combined stroke and TIA</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dacron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTFE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.14008884852644" CI_START="1.2044594566406577" DF="0" EFFECT_SIZE="4.409090909090909" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="1.2079059211121081" LOG_CI_START="0.080792185775969" LOG_EFFECT_SIZE="0.6443490534440386" MODIFIED="2009-09-20 10:55:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02502952366986071" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="2.2409467627437887">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="16.14008884852644" CI_START="1.2044594566406577" EFFECT_SIZE="4.409090909090909" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.2079059211121081" LOG_CI_START="0.080792185775969" LOG_EFFECT_SIZE="0.6443490534440386" ORDER="78419" O_E="0.0" SE="0.66207218743942" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="0.43833958138081847" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.259877625932087" CI_END="3.56601839776978" CI_START="0.2971704019645433" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.029424655173074" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="7.972005570539812" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.5521835794532683" LOG_CI_START="-0.5269944482882865" LOG_EFFECT_SIZE="0.012594565582490953" METHOD="MH" MODIFIED="2009-10-01 12:30:48 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.35326614307392257" P_Q="0.0" P_Z="0.9635114351565576" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="303" WEIGHT="100.0" Z="0.045747586233328356">
<NAME>Death from all causes</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dacron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTFE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4727845698371276" CI_END="9.066631282147226" CI_START="0.2498199087967743" DF="1" EFFECT_SIZE="1.5050000000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="32.101407057069586" ID="CMP-002.04.01" LOG_CI_END="0.9574459543882651" LOG_CI_START="-0.6023729545285407" LOG_EFFECT_SIZE="0.1775364999298622" MODIFIED="2009-09-20 10:55:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.224907187394896" P_Z="0.6554809871632472" STUDIES="2" TAU2="0.0" TOTAL_1="200" TOTAL_2="200" WEIGHT="40.37046042133183" Z="0.4461609534474323">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="107.61844941138509" CI_START="0.241831539632091" EFFECT_SIZE="5.101522842639594" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.031886730351894" LOG_CI_START="-0.6164870591620649" LOG_EFFECT_SIZE="0.7076998355949148" ORDER="78420" O_E="0.0" SE="1.5556678736221876" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="2.4201025330201786" WEIGHT="9.941225878752963"/>
<DICH_DATA CI_END="8.198699712865304" CI_START="0.013283929081797059" EFFECT_SIZE="0.33001658374792703" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9137449801513373" LOG_CI_START="-1.8766734516122263" LOG_EFFECT_SIZE="-0.48146423573044467" MODIFIED="2009-09-15 11:47:14 +0100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="1.6391055996119246" STUDY_ID="STD-AbuRahma-2007" TOTAL_1="100" TOTAL_2="100" VAR="2.686667166679167" WEIGHT="30.429234542578868"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="89.42398982176422" CI_START="0.14106666876645826" DF="0" EFFECT_SIZE="3.5517241379310347" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="1.951454042840448" LOG_CI_START="-0.8505755892280158" LOG_EFFECT_SIZE="0.5504392268062162" MODIFIED="2009-09-20 12:37:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4412746429789828" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="51" WEIGHT="9.142660714490795" Z="0.7700425776167509">
<NAME>Bovine pericardium</NAME>
<DICH_DATA CI_END="89.4239898217643" CI_START="0.1410666687664582" EFFECT_SIZE="3.5517241379310347" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9514540428404483" LOG_CI_START="-0.850575589228016" LOG_EFFECT_SIZE="0.5504392268062162" MODIFIED="2009-09-20 12:37:46 +0100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="1.6459260761473915" STUDY_ID="STD-Marien-2002" TOTAL_1="44" TOTAL_2="51" VAR="2.7090726481419485" WEIGHT="9.142660714490795"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.106462934853439" CI_START="0.009012727358349622" DF="0" EFFECT_SIZE="0.19238095238095237" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.6134679072165974" LOG_CI_START="-2.0451437664632257" LOG_EFFECT_SIZE="-0.7158379296233144" MODIFIED="2009-10-01 08:40:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.29121933510399733" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="50.48687886417737" Z="1.0554505381280286">
<NAME>Polyurethane</NAME>
<DICH_DATA CI_END="4.106462934853437" CI_START="0.00901272735834963" EFFECT_SIZE="0.19238095238095237" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6134679072165972" LOG_CI_START="-2.0451437664632257" LOG_EFFECT_SIZE="-0.7158379296233144" MODIFIED="2009-10-01 08:40:37 +0100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="1.56168165745956" STUDY_ID="STD-Albrecht_x002d_Fruh-1998" TOTAL_1="52" TOTAL_2="52" VAR="2.4388495992456387" WEIGHT="50.48687886417737"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08583680758710549" CI_END="31.89747279268679" CI_START="0.9227667752404561" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="5.425304425304425" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.5037562756694498" LOG_CI_START="-0.034908050897257084" LOG_EFFECT_SIZE="0.7344241123860964" METHOD="MH" MODIFIED="2009-10-01 12:30:48 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.769538068680353" P_Q="0.0" P_Z="0.06134069733567984" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="151" WEIGHT="100.0" Z="1.8710316276278998">
<NAME>Complication requiring further operation</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dacron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTFE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.480719964376284" CI_START="0.7466549310499138" DF="0" EFFECT_SIZE="6.319148936170213" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="1.7281972451578438" LOG_CI_START="-0.1268800623948541" LOG_EFFECT_SIZE="0.8006585913814949" MODIFIED="2009-09-20 10:56:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09067339889841435" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="67.7012177012177" Z="1.6918561793961497">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="53.480719964376284" CI_START="0.7466549310499138" EFFECT_SIZE="6.319148936170213" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7281972451578438" LOG_CI_START="-0.1268800623948541" LOG_EFFECT_SIZE="0.8006585913814949" ORDER="78421" O_E="0.0" SE="1.089681593237225" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="1.1874059746400172" WEIGHT="67.7012177012177"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="89.42398982176422" CI_START="0.14106666876645826" DF="0" EFFECT_SIZE="3.5517241379310347" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="1.951454042840448" LOG_CI_START="-0.8505755892280158" LOG_EFFECT_SIZE="0.5504392268062162" MODIFIED="2009-09-20 12:39:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4412746429789828" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="51" WEIGHT="32.2987822987823" Z="0.7700425776167509">
<NAME>Bovine pericardium</NAME>
<DICH_DATA CI_END="89.4239898217643" CI_START="0.1410666687664582" EFFECT_SIZE="3.5517241379310347" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9514540428404483" LOG_CI_START="-0.850575589228016" LOG_EFFECT_SIZE="0.5504392268062162" MODIFIED="2009-09-20 12:39:54 +0100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="1.6459260761473915" STUDY_ID="STD-Marien-2002" TOTAL_1="44" TOTAL_2="51" VAR="2.7090726481419485" WEIGHT="32.2987822987823"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="212.1943285289018" CI_START="0.6315052692570472" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="11.575916230366492" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="2.3267337720181103" LOG_CI_START="-0.19962302135613721" LOG_EFFECT_SIZE="1.0635553753309863" METHOD="MH" MODIFIED="2009-10-01 12:30:48 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.09889665645897938" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="1.65022631536425">
<NAME>Arterial occlusion</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dacron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTFE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="212.1943285289018" CI_START="0.6315052692570472" DF="0" EFFECT_SIZE="11.575916230366492" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="2.3267337720181103" LOG_CI_START="-0.19962302135613721" LOG_EFFECT_SIZE="1.0635553753309863" MODIFIED="2009-09-20 10:56:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09889665645897938" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="1.65022631536425">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="212.1943285289018" CI_START="0.6315052692570472" EFFECT_SIZE="11.575916230366492" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3267337720181103" LOG_CI_START="-0.19962302135613721" LOG_EFFECT_SIZE="1.0635553753309863" ORDER="78422" O_E="0.0" SE="1.483994486095849" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="2.2022396347628828" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04046377947228269" CI_END="28.03872692236272" CI_START="1.877929960987543" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="7.25636033803814" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="1.4477582909228484" LOG_CI_START="0.27367939084604237" LOG_EFFECT_SIZE="0.8607188408844453" METHOD="MH" MODIFIED="2009-10-01 12:30:48 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8405766109731069" P_Q="0.0" P_Z="0.004056882984347359" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="200" WEIGHT="100.0" Z="2.873704533550881">
<NAME>Early restenosis or occlusion</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dacron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTFE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04046377947228269" CI_END="28.03872692236272" CI_START="1.877929960987543" DF="1" EFFECT_SIZE="7.25636033803814" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="1.4477582909228484" LOG_CI_START="0.27367939084604237" LOG_EFFECT_SIZE="0.8607188408844453" MODIFIED="2009-09-20 10:56:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8405766109731069" P_Z="0.004056882984347359" STUDIES="2" TAU2="0.0" TOTAL_1="200" TOTAL_2="200" WEIGHT="100.0" Z="2.873704533550881">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="30.684562207735567" CI_START="1.4550213854320733" EFFECT_SIZE="6.681818181818182" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.4869199313637669" LOG_CI_START="0.16286937648817304" LOG_EFFECT_SIZE="0.8248946539259698" ORDER="78423" O_E="0.0" SE="0.7777538500898744" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="0.6049010513296228" WEIGHT="78.65138710676518"/>
<DICH_DATA CI_END="176.42648707445824" CI_START="0.497964896796031" EFFECT_SIZE="9.373056994818652" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.24656378672972" LOG_CI_START="-0.3028012710256402" LOG_EFFECT_SIZE="0.9718812578520399" MODIFIED="2009-09-15 11:49:19 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="1.4975096544860602" STUDY_ID="STD-AbuRahma-2007" TOTAL_1="100" TOTAL_2="100" VAR="2.2425351652789596" WEIGHT="21.34861289323481"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-01-27 09:55:32 +0000" MODIFIED_BY="Hazel Fraser" NO="3">
<NAME>Events during long-term (&gt; 1 year) follow-up: synthetic versus vein</NAME>
<DICH_OUTCOME CHI2="1.140217160197888" CI_END="3.0652079252287487" CI_START="0.6892713485930777" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4535336254592148" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.4864599397734206" LOG_CI_START="-0.16160977374219493" LOG_EFFECT_SIZE="0.16242508301561281" METHOD="MH" NO="1" P_CHI2="0.7673754722221081" P_Q="0.0" P_Z="0.3258793294165375" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="389" TOTAL_2="387" WEIGHT="100.0" Z="0.9824477405974593">
<NAME>Ipsilateral stroke</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.089876617178633" CI_END="3.8779582595564355" CI_START="0.47468203509547785" DF="2" EFFECT_SIZE="1.3567597866466878" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.5886031302347261" LOG_CI_START="-0.3235972043602983" LOG_EFFECT_SIZE="0.13250296293721392" NO="1" P_CHI2="0.5798776747000493" P_Z="0.5690882898160492" STUDIES="3" TAU2="0.0" TOTAL_1="252" TOTAL_2="248" WEIGHT="52.05274810804593" Z="0.5693947378720934">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="28.772466820033642" CI_START="0.3033208335639715" EFFECT_SIZE="2.954198473282443" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4589770979140253" LOG_CI_START="-0.5180977591877312" LOG_EFFECT_SIZE="0.4704396693631472" ORDER="78424" O_E="0.0" SE="1.161343557739952" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="1.348718859104089" WEIGHT="8.550252719605682"/>
<DICH_DATA CI_END="69.41987770623592" CI_START="0.10953957727998762" EFFECT_SIZE="2.757575757575758" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8414838442597135" LOG_CI_START="-0.9604289393733008" LOG_EFFECT_SIZE="0.4405274524432061" ORDER="78425" O_E="0.0" SE="1.645857438797999" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="2.7088467088467088" WEIGHT="4.3965807247897635"/>
<DICH_DATA CI_END="3.3063732636867336" CI_START="0.21851737307916186" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5193518804540701" LOG_CI_START="-0.6605140290254847" LOG_EFFECT_SIZE="-0.07058107428570727" ORDER="78426" O_E="0.0" SE="0.6930590756587357" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="0.4803308823529412" WEIGHT="39.10591466365049"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.205243953548514E-32" CI_END="4.503701575149452" CI_START="0.5393817589830984" DF="0" EFFECT_SIZE="1.5585937499999998" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="99.99999999999999" ID="CMP-003.01.02" LOG_CI_END="0.6535696055200908" LOG_CI_START="-0.26810374477029353" LOG_EFFECT_SIZE="0.1927329303748986" NO="2" P_CHI2="0.0" P_Z="0.4123849558342816" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="139" WEIGHT="47.94725189195407" Z="0.8197038615701594">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="4.503701575149452" CI_START="0.5393817589830985" EFFECT_SIZE="1.55859375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6535696055200908" LOG_CI_START="-0.2681037447702935" LOG_EFFECT_SIZE="0.19273293037489866" ORDER="78427" O_E="0.0" SE="0.5413954883172365" STUDY_ID="STD-Hayes-2001" TOTAL_1="137" TOTAL_2="139" VAR="0.293109074770259" WEIGHT="47.94725189195407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.986716941214258" CI_END="2.128974685560414" CI_START="0.6985429291853203" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2194999848350832" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.32817049751780325" LOG_CI_START="-0.15580689901951764" LOG_EFFECT_SIZE="0.08618179924914281" METHOD="MH" MODIFIED="2009-10-01 11:54:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6784742758745088" P_Q="0.0" P_Z="0.48516398981265985" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="588" WEIGHT="100.0" Z="0.6980211218940908">
<NAME>Any stroke</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4790355885317132" CI_END="4.176520325859731" CI_START="0.6257177403127347" DF="3" EFFECT_SIZE="1.616577514586652" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.6208145993267543" LOG_CI_START="-0.20362153175620434" LOG_EFFECT_SIZE="0.20859653378527493" MODIFIED="2009-10-01 11:54:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6871173149402314" P_Z="0.3212905939648284" STUDIES="4" TAU2="0.0" TOTAL_1="306" TOTAL_2="303" WEIGHT="30.58640340165535" Z="0.9918092575151634">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="28.772466820033642" CI_START="0.3033208335639715" EFFECT_SIZE="2.954198473282443" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4589770979140253" LOG_CI_START="-0.5180977591877312" LOG_EFFECT_SIZE="0.4704396693631472" ORDER="78428" O_E="0.0" SE="1.161343557739952" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="1.348718859104089" WEIGHT="4.414638157647112"/>
<DICH_DATA CI_END="70.13509068380634" CI_START="0.1091044322441954" EFFECT_SIZE="2.7662337662337664" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8459353628635324" LOG_CI_START="-0.9621576063310207" LOG_EFFECT_SIZE="0.4418888782662559" ORDER="78429" O_E="0.0" SE="1.649487710389259" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="39" TOTAL_2="35" VAR="2.7208097067251997" WEIGHT="2.2534342222943575"/>
<DICH_DATA CI_END="30.23763581733053" CI_START="0.3133050604548395" EFFECT_SIZE="3.0779220779220777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4805478320796417" LOG_CI_START="-0.5040325904043979" LOG_EFFECT_SIZE="0.488257620837622" MODIFIED="2009-10-01 11:54:19 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="1.165752363998653" STUDY_ID="STD-Grego-2003" TOTAL_1="80" TOTAL_2="80" VAR="1.3589785741684477" WEIGHT="4.28152502235928"/>
<DICH_DATA CI_END="3.4085569511527654" CI_START="0.21966911402036618" EFFECT_SIZE="0.8653061224489796" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5325705547125754" LOG_CI_START="-0.6582310015841374" LOG_EFFECT_SIZE="-0.06283022343578101" ORDER="78430" O_E="0.0" SE="0.6994827287314591" STUDY_ID="STD-Ricco-1996" TOTAL_1="53" TOTAL_2="58" VAR="0.48927608779360804" WEIGHT="19.6368059993546"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5990592859405701" CI_END="2.8724684444632183" CI_START="0.6008692584723565" DF="1" EFFECT_SIZE="1.3137648131267092" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.4582552664392532" LOG_CI_START="-0.22122001468761363" LOG_EFFECT_SIZE="0.11851762587581975" NO="2" P_CHI2="0.4389373393894811" P_Z="0.4941429640608441" STUDIES="2" TAU2="0.0" TOTAL_1="231" TOTAL_2="240" WEIGHT="48.96146930837645" Z="0.6837343011641582">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="4.3801019240943475" CI_START="0.618745204332581" EFFECT_SIZE="1.6462585034013606" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6414842165672786" LOG_CI_START="-0.20848815410276816" LOG_EFFECT_SIZE="0.2164980312322552" ORDER="78431" O_E="0.0" SE="0.49927797796267687" STUDY_ID="STD-Hayes-2001" TOTAL_1="137" TOTAL_2="139" VAR="0.24927849927849927" WEIGHT="28.43067999036992"/>
<DICH_DATA CI_END="3.278089199897822" CI_START="0.22213482714273772" EFFECT_SIZE="0.8533333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5156207669575867" LOG_CI_START="-0.6533833457732123" LOG_EFFECT_SIZE="-0.06888128940781285" ORDER="78432" O_E="0.0" SE="0.6866788024817555" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="0.4715277777777778" WEIGHT="20.530789318006534"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1838467133842108" CI_START="0.07326521546562904" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.33922215149254537" LOG_CI_START="-1.1351021688366205" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2009-10-01 11:47:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2900365833681292" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="20.452127289968196" Z="1.0580414014070052">
<NAME>Polyester</NAME>
<DICH_DATA CI_END="2.183846713384211" CI_START="0.07326521546562902" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3392221514925454" LOG_CI_START="-1.1351021688366205" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2009-10-01 11:47:29 +0100" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.8660254037844387" STUDY_ID="STD-Meerwaldt-2008" TOTAL_1="42" TOTAL_2="45" VAR="0.7500000000000001" WEIGHT="20.452127289968196"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2303549074611503" CI_END="1.3568650741283679" CI_START="0.5864219069331136" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8920176030893662" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.1325366638167946" LOG_CI_START="-0.23178981414718713" LOG_EFFECT_SIZE="-0.04962657516519627" METHOD="MH" MODIFIED="2009-10-01 11:58:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.999766361668697" P_Q="0.0" P_Z="0.5933752238405015" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="588" WEIGHT="99.99999999999999" Z="0.5339513095145975">
<NAME>Death from all causes</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.09544677782874958" CI_END="1.590393862389139" CI_START="0.4968324969497673" DF="3" EFFECT_SIZE="0.8889090807188216" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.20150469103734747" LOG_CI_START="-0.3037900054554877" LOG_EFFECT_SIZE="-0.051142657209070096" MODIFIED="2009-10-01 11:58:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9923781734480128" P_Z="0.6915520280751747" STUDIES="4" TAU2="0.0" TOTAL_1="306" TOTAL_2="303" WEIGHT="52.07383042662982" Z="0.396749726047744">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="2.129895911218128" CI_START="0.3573607099992877" EFFECT_SIZE="0.8724340175953079" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3283583798292664" LOG_CI_START="-0.44689319768512514" LOG_EFFECT_SIZE="-0.059267408927929345" ORDER="78433" O_E="0.0" SE="0.45538661418915355" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.20737696838266098" WEIGHT="22.317216918319502"/>
<DICH_DATA CI_END="6.692269863702413" CI_START="0.11886417658334149" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8255734454334769" LOG_CI_START="-0.9249490138116919" LOG_EFFECT_SIZE="-0.04968778418910752" ORDER="78434" O_E="0.0" SE="1.0282655577865365" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="39" TOTAL_2="35" VAR="1.0573300573300572" WEIGHT="4.319461339029581"/>
<DICH_DATA CI_END="3.419081140029109" CI_START="0.1602724418072023" EFFECT_SIZE="0.7402597402597403" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5339094073917297" LOG_CI_START="-0.7951411463917104" LOG_EFFECT_SIZE="-0.13061586949999046" MODIFIED="2009-10-01 11:58:38 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.7806908741987372" STUDY_ID="STD-Grego-2003" TOTAL_1="80" TOTAL_2="80" VAR="0.6094782410571885" WEIGHT="8.314963077631944"/>
<DICH_DATA CI_END="2.639915396787551" CI_START="0.36515069510249776" EFFECT_SIZE="0.9818181818181818" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.4215900089542738" LOG_CI_START="-0.43752786829682444" LOG_EFFECT_SIZE="-0.00796892967127534" ORDER="78435" O_E="0.0" SE="0.5046500937993742" STUDY_ID="STD-Ricco-1996" TOTAL_1="53" TOTAL_2="58" VAR="0.25467171717171716" WEIGHT="17.12218909164879"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09959541689759094" CI_END="1.6591513194001823" CI_START="0.4658595090933503" DF="1" EFFECT_SIZE="0.8791651830955053" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.219885996743839" LOG_CI_START="-0.331745035294462" LOG_EFFECT_SIZE="-0.055929519275311486" NO="2" P_CHI2="0.7523157159496259" P_Z="0.6910437602562318" STUDIES="2" TAU2="0.0" TOTAL_1="231" TOTAL_2="240" WEIGHT="43.95425110069929" Z="0.39743900210689426">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="1.7009907649829026" CI_START="0.41003653901237086" EFFECT_SIZE="0.8351457155284906" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.23070195574786992" LOG_CI_START="-0.38717744087932887" LOG_EFFECT_SIZE="-0.07823774256572945" ORDER="78436" O_E="0.0" SE="0.36294541613115755" STUDY_ID="STD-Hayes-2001" TOTAL_1="137" TOTAL_2="139" VAR="0.1317293750906191" WEIGHT="35.97986093633698"/>
<DICH_DATA CI_END="4.437896116341201" CI_START="0.2617467619384664" EFFECT_SIZE="1.0777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6471771319140567" LOG_CI_START="-0.5821186822602167" LOG_EFFECT_SIZE="0.03252922482691995" ORDER="78437" O_E="0.0" SE="0.7220944463583877" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="0.5214203894616265" WEIGHT="7.974390164362304"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.996607073714919" CI_START="0.1445144158450117" DF="0" EFFECT_SIZE="1.075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.9029057567763208" LOG_CI_START="-0.8400888282730725" LOG_EFFECT_SIZE="0.031408464251624114" MODIFIED="2009-10-01 11:48:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9436871147306609" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="3.971918472670879" Z="0.07063643142775751">
<NAME>Polyester</NAME>
<DICH_DATA CI_END="7.996607073714919" CI_START="0.1445144158450117" EFFECT_SIZE="1.075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9029057567763208" LOG_CI_START="-0.8400888282730725" LOG_EFFECT_SIZE="0.031408464251624114" MODIFIED="2009-10-01 11:48:00 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="1.0238436472203596" STUDY_ID="STD-Meerwaldt-2008" TOTAL_1="42" TOTAL_2="45" VAR="1.0482558139534883" WEIGHT="3.971918472670879"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08541407997553715" CI_END="2.8842547380441017" CI_START="0.2597695167331956" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8655873493975903" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.4600336147302098" LOG_CI_START="-0.5854118135836116" LOG_EFFECT_SIZE="-0.06268909942670087" METHOD="MH" NO="4" P_CHI2="0.7700902428201049" P_Q="0.0" P_Z="0.8141663577188084" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="363" TOTAL_2="362" WEIGHT="100.0" Z="0.23505459734566206">
<NAME>Fatal stroke</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.08384371798439" CI_START="0.14914812325015522" DF="0" EFFECT_SIZE="1.0980392156862746" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.9076179088668843" LOG_CI_START="-0.8263822070503563" LOG_EFFECT_SIZE="0.040617850908264086" NO="1" P_CHI2="1.0" P_Z="0.9268396059391314" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="223" WEIGHT="32.11938663745892" Z="0.09182182190051792">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78438" O_E="0.0" SE="0.0" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78439" O_E="0.0" SE="0.0" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="39" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.08384371798439" CI_START="0.14914812325015522" EFFECT_SIZE="1.0980392156862746" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9076179088668843" LOG_CI_START="-0.8263822070503563" LOG_EFFECT_SIZE="0.040617850908264086" ORDER="78440" O_E="0.0" SE="1.0185602515287928" STUDY_ID="STD-Ricco-1996" TOTAL_1="53" TOTAL_2="58" VAR="1.0374649859943976" WEIGHT="32.11938663745892"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4406480490238267" CI_START="0.165935847209399" DF="0" EFFECT_SIZE="0.7555970149253731" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.5366402500157934" LOG_CI_START="-0.7800597829719964" LOG_EFFECT_SIZE="-0.12170976647810146" NO="2" P_CHI2="1.0" P_Z="0.7170977283533766" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="139" WEIGHT="67.88061336254107" Z="0.36234032488411333">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="3.440648049023828" CI_START="0.165935847209399" EFFECT_SIZE="0.7555970149253731" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5366402500157936" LOG_CI_START="-0.7800597829719964" LOG_EFFECT_SIZE="-0.12170976647810146" ORDER="78441" O_E="0.0" SE="0.7734361171473084" STUDY_ID="STD-Hayes-2001" TOTAL_1="137" TOTAL_2="139" VAR="0.598203427307905" WEIGHT="67.88061336254107"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18843751429731034" CI_END="1.5610617214514197" CI_START="0.702016082228389" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0468478560946812" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.19342007459082514" LOG_CI_START="-0.15365293866357985" LOG_EFFECT_SIZE="0.01988356796362266" METHOD="MH" NO="5" P_CHI2="0.995830604756462" P_Q="0.0" P_Z="0.8223138781124422" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="457" TOTAL_2="463" WEIGHT="100.0" Z="0.22456990664548726">
<NAME>Stroke or death</NAME>
<GROUP_LABEL_1>Syntetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.17196425006662774" CI_END="1.8162641590387916" CI_START="0.5716587359762672" DF="2" EFFECT_SIZE="1.0189618605988713" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.25917901294596646" LOG_CI_START="-0.2428631553186621" LOG_EFFECT_SIZE="0.008157928813652215" NO="1" P_CHI2="0.9176106697894486" P_Z="0.9492116310066318" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="223" WEIGHT="48.44263635680491" Z="0.0636968273739584">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="2.409718283403136" CI_START="0.46318150942132935" EFFECT_SIZE="1.056473829201102" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.38196627281762374" LOG_CI_START="-0.3342487863198492" LOG_EFFECT_SIZE="0.023858743248887274" ORDER="78442" O_E="0.0" SE="0.42070827105907255" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.17699544933751407" WEIGHT="23.388081847235586"/>
<DICH_DATA CI_END="8.749079135668726" CI_START="0.21609417067588244" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9419623447544756" LOG_CI_START="-0.6653569484219127" LOG_EFFECT_SIZE="0.13830269816628143" ORDER="78443" O_E="0.0" SE="0.9441473091706302" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="39" TOTAL_2="35" VAR="0.8914141414141414" WEIGHT="4.137449368552733"/>
<DICH_DATA CI_END="2.2441625441535624" CI_START="0.3662442397587741" EFFECT_SIZE="0.9065934065934066" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.3510543095682656" LOG_CI_START="-0.4362291971106026" LOG_EFFECT_SIZE="-0.042587443771168514" ORDER="78444" O_E="0.0" SE="0.46245422893937715" STUDY_ID="STD-Ricco-1996" TOTAL_1="53" TOTAL_2="58" VAR="0.21386391386391387" WEIGHT="20.917105141016595"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3213982611000495E-4" CI_END="1.8655152868162663" CI_START="0.6172206408339925" DF="1" EFFECT_SIZE="1.0730491791219754" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.2707988121829315" LOG_CI_START="-0.20955955887198938" LOG_EFFECT_SIZE="0.030619626655471046" NO="2" P_CHI2="0.9908283523502017" P_Z="0.8026885527456854" STUDIES="2" TAU2="0.0" TOTAL_1="231" TOTAL_2="240" WEIGHT="51.55736364319509" Z="0.24986913554973472">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="2.0069357904642255" CI_START="0.5717319005085587" EFFECT_SIZE="1.0711812235475182" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.30253347797171326" LOG_CI_START="-0.2428075750966895" LOG_EFFECT_SIZE="0.029862951437511873" ORDER="78445" O_E="0.0" SE="0.32033603405412914" STUDY_ID="STD-Hayes-2001" TOTAL_1="137" TOTAL_2="139" VAR="0.1026151747135282" WEIGHT="40.04323104147911"/>
<DICH_DATA CI_END="3.4718604086841487" CI_START="0.3356754740238681" EFFECT_SIZE="1.0795454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5405622553993525" LOG_CI_START="-0.47408038912199424" LOG_EFFECT_SIZE="0.03324093313867916" ORDER="78446" O_E="0.0" SE="0.5960061119539324" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="94" TOTAL_2="101" VAR="0.35522328548644333" WEIGHT="11.514132601715982"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="69.41987770623592" CI_START="0.10953957727998762" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.757575757575758" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="1.8414838442597135" LOG_CI_START="-0.9604289393733008" LOG_EFFECT_SIZE="0.4405274524432061" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.5376925307680358" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="118" WEIGHT="100.0" Z="0.6163060792137444">
<NAME>Infection at endarterectomy site</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vein</GRAPH_LABEL_2>
<DICH_DATA CI_END="69.41987770623592" CI_START="0.10953957727998762" EFFECT_SIZE="2.757575757575758" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8414838442597135" LOG_CI_START="-0.9604289393733008" LOG_EFFECT_SIZE="0.4405274524432061" ORDER="78447" O_E="0.0" SE="1.645857438797999" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="2.7088467088467088" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78448" O_E="0.0" SE="0.0" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.6960490780707875" CI_END="1.5711482470681049" CI_START="0.6095918791993337" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9786517319409316" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" I2="35.03159934040625" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.19621716520934893" LOG_CI_START="-0.2149608271710962" LOG_EFFECT_SIZE="-0.009371830980873654" METHOD="MH" MODIFIED="2009-09-15 08:50:10 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.17380176382282042" P_Q="0.0" P_Z="0.9288073366720457" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="573" TOTAL_2="575" WEIGHT="100.00000000000001" Z="0.08934549772651025">
<NAME>Arterial occlusions/restenosis &gt; 50%</NAME>
<GROUP_LABEL_1>Syntheic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.831961259511578" CI_END="1.218479575201341" CI_START="0.2892504336520638" DF="3" EFFECT_SIZE="0.5936714120817764" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" I2="21.71110831161221" ID="CMP-003.07.01" LOG_CI_END="0.0858182537081078" LOG_CI_START="-0.5387259812697056" LOG_EFFECT_SIZE="-0.22645386378079893" MODIFIED="2009-09-15 08:43:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.28019066317341823" P_Z="0.15522113592136275" STUDIES="4" TAU2="0.0" TOTAL_1="332" TOTAL_2="328" WEIGHT="57.140554280226056" Z="1.4213290022157439">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="0.9095083395829627" CI_START="0.0674841504523458" EFFECT_SIZE="0.2477446217904233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.04119331439240841" LOG_CI_START="-1.170798215011184" LOG_EFFECT_SIZE="-0.6059957647017962" ORDER="78449" O_E="0.0" SE="0.6635355102579075" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.4402793733732216" WEIGHT="31.495236759950565"/>
<DICH_DATA CI_END="100.36129608213663" CI_START="0.21923660267336104" EFFECT_SIZE="4.690721649484536" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.001566261228518" LOG_CI_START="-0.6590869364467827" LOG_EFFECT_SIZE="0.6712396623908676" ORDER="78450" O_E="0.0" SE="1.5628808587602103" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="2.4425965786790527" WEIGHT="1.4425299279366672"/>
<DICH_DATA CI_END="3.419081140029109" CI_START="0.1602724418072023" EFFECT_SIZE="0.7402597402597403" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5339094073917297" LOG_CI_START="-0.7951411463917104" LOG_EFFECT_SIZE="-0.13061586949999046" MODIFIED="2009-09-15 08:43:23 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.7806908741987372" STUDY_ID="STD-Grego-2003" TOTAL_1="80" TOTAL_2="80" VAR="0.6094782410571885" WEIGHT="11.107480445112339"/>
<DICH_DATA CI_END="3.3063732636867336" CI_START="0.21851737307916186" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5193518804540701" LOG_CI_START="-0.6605140290254847" LOG_EFFECT_SIZE="-0.07058107428570727" ORDER="78451" O_E="0.0" SE="0.6930590756587357" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="0.4803308823529412" WEIGHT="13.095307147226483"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6889710638395987" CI_END="2.8708892873064684" CI_START="0.7752988342849777" DF="1" EFFECT_SIZE="1.4919105595879183" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.4580164447295333" LOG_CI_START="-0.1105308690215699" LOG_EFFECT_SIZE="0.1737427878539817" NO="2" P_CHI2="0.406514969869496" P_Z="0.2309584461667452" STUDIES="2" TAU2="0.0" TOTAL_1="199" TOTAL_2="202" WEIGHT="42.85944571977396" Z="1.1978936441390462">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="4.148085906877698" CI_START="0.8051318909433736" EFFECT_SIZE="1.8275" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.6178477420508042" LOG_CI_START="-0.09413297079100803" LOG_EFFECT_SIZE="0.2618573856298981" ORDER="78452" O_E="0.0" SE="0.4182209950846492" STUDY_ID="STD-Hayes-2001" TOTAL_1="137" TOTAL_2="139" VAR="0.1749088007295942" WEIGHT="25.087477007594213"/>
<DICH_DATA CI_END="3.09495914373543" CI_START="0.33496216483969643" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.49065492031336794" LOG_CI_START="-0.4750042452894549" LOG_EFFECT_SIZE="0.007825337511956526" ORDER="78453" O_E="0.0" SE="0.5672329739650602" STUDY_ID="STD-O_x0027_Hara-2002" TOTAL_1="62" TOTAL_2="63" VAR="0.32175324675324674" WEIGHT="17.771968712179742"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-15 08:50:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Polyester</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-15 08:50:10 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Meerwaldt-2008" TOTAL_1="42" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0884520351375151" CI_END="0.48873129711130975" CI_START="0.015777055028893684" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.08781082261810173" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-0.310929848965427" LOG_CI_START="-1.8019740596856675" LOG_EFFECT_SIZE="-1.056451954325547" METHOD="MH" MODIFIED="2010-01-12 16:18:32 +0000" MODIFIED_BY="Hazel Fraser" NO="8" P_CHI2="0.7661543884884562" P_Q="0.0" P_Z="0.005479690021737991" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="389" TOTAL_2="387" WEIGHT="100.0" Z="2.777392872710101">
<NAME>Pseudoaneurysm formation</NAME>
<GROUP_LABEL_1>Synthetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synthetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vein</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0884520351375151" CI_END="0.48873129711130975" CI_START="0.015777055028893684" DF="1" EFFECT_SIZE="0.08781082261810173" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="-0.310929848965427" LOG_CI_START="-1.8019740596856675" LOG_EFFECT_SIZE="-1.056451954325547" NO="1" P_CHI2="0.7661543884884562" P_Z="0.005479690021737991" STUDIES="3" TAU2="0.0" TOTAL_1="252" TOTAL_2="248" WEIGHT="100.0" Z="2.777392872710101">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78454" O_E="0.0" SE="0.0" STUDY_ID="STD-AbuRahma-1996" TOTAL_1="134" TOTAL_2="130" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9394578210267013" CI_START="0.013064766940710475" EFFECT_SIZE="0.11078717201166181" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.027122713707750327" LOG_CI_START="-1.8838983331441703" LOG_EFFECT_SIZE="-0.9555105234259603" ORDER="78455" O_E="0.0" SE="1.090679190044503" STUDY_ID="STD-Gonzalez-1994" TOTAL_1="50" TOTAL_2="45" VAR="1.1895810955961332" WEIGHT="50.12403524593724"/>
<DICH_DATA CI_END="1.1558596444429332" CI_START="0.0036238860101309744" EFFECT_SIZE="0.06472019464720194" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.0629051010873666" LOG_CI_START="-2.440825471577371" LOG_EFFECT_SIZE="-1.1889601852450022" ORDER="78456" O_E="0.0" SE="1.4707037320494842" STUDY_ID="STD-Ricco-1996" TOTAL_1="68" TOTAL_2="73" VAR="2.1629694674642814" WEIGHT="49.87596475406276"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="139" WEIGHT="0.0" Z="0.0">
<NAME>Dacron</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78457" O_E="0.0" SE="0.0" STUDY_ID="STD-Hayes-2001" TOTAL_1="137" TOTAL_2="139" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-01-27 09:55:57 +0000" MODIFIED_BY="Hazel Fraser" NO="4">
<NAME>Event during long-term (&gt; 1 year) follow-up: Dacron versus other synthetic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.270184708841223" CI_START="0.247743810663471" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5154639175257731" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.9670883875675091" LOG_CI_START="-0.6059971866036467" LOG_EFFECT_SIZE="0.18054560048193122" METHOD="MH" MODIFIED="2009-10-01 12:31:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6527850475524632" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="0.4498965349652892">
<NAME>Ipsilateral stroke</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>Other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.270184708841223" CI_START="0.247743810663471" EFFECT_SIZE="1.5154639175257731" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9670883875675091" LOG_CI_START="-0.6059971866036467" LOG_EFFECT_SIZE="0.18054560048193122" MODIFIED="2009-10-01 12:10:59 +0100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.9240382531673145" STUDY_ID="STD-AbuRahma-2007" TOTAL_1="100" TOTAL_2="100" VAR="0.8538466933165019" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.28952328657785853" CI_END="83.43178235467926" CI_START="1.3420936931506637" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="10.581742243436754" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="1.9213315215238165" LOG_CI_START="0.12778283550359112" LOG_EFFECT_SIZE="1.0245571785137038" METHOD="MH" MODIFIED="2009-10-01 12:31:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5905262558177485" P_Q="0.0" P_Z="0.025140145670794013" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="152" WEIGHT="100.0" Z="2.2392424422496995">
<NAME>Any stroke</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>Other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="286.2243030867659" CI_START="0.9082071429927612" DF="0" EFFECT_SIZE="16.122994652406415" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="2.4567065066018405" LOG_CI_START="-0.041815086722498465" LOG_EFFECT_SIZE="1.2074457099396712" MODIFIED="2009-10-01 12:08:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05817719716960129" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="49.27903739061257" Z="1.894360337803128">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="286.2243030867659" CI_START="0.9082071429927607" EFFECT_SIZE="16.122994652406415" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4567065066018405" LOG_CI_START="-0.04181508672249867" LOG_EFFECT_SIZE="1.2074457099396712" MODIFIED="2009-09-15 12:23:17 +0100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="1.4676439518000706" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="2.153978769255328" WEIGHT="49.27903739061257"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="110.95420511900589" CI_START="0.2435185744677105" DF="0" EFFECT_SIZE="5.198019801980198" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="2.045143766463226" LOG_CI_START="-0.6134679072165973" LOG_EFFECT_SIZE="0.7158379296233144" MODIFIED="2009-09-20 11:04:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.29121933510399733" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="50.72096260938743" Z="1.0554505381280286">
<NAME>Polyurethane</NAME>
<DICH_DATA CI_END="110.95420511900579" CI_START="0.24351857446771058" EFFECT_SIZE="5.198019801980198" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0451437664632257" LOG_CI_START="-0.6134679072165972" LOG_EFFECT_SIZE="0.7158379296233144" MODIFIED="2009-09-20 11:04:03 +0100" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="1.56168165745956" STUDY_ID="STD-Albrecht_x002d_Fruh-1998" TOTAL_1="52" TOTAL_2="52" VAR="2.4388495992456387" WEIGHT="50.72096260938743"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.132408799383933" CI_END="2.7195289960950397" CI_START="0.5229740404825732" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1925783275312942" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="85.97949124724349" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.4344936936997976" LOG_CI_START="-0.28151986821681635" LOG_EFFECT_SIZE="0.07648691274149061" METHOD="MH" MODIFIED="2010-01-12 16:19:21 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.007570316488755169" P_Q="0.0" P_Z="0.6754064973632714" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="152" WEIGHT="100.0" Z="0.4187395385659969">
<NAME>Death</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>Other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0641931637534325" CI_START="0.014930286122593065" DF="0" EFFECT_SIZE="0.12605042016806722" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.02702046474309449" LOG_CI_START="-1.8259318694167936" LOG_EFFECT_SIZE="-0.8994557023368495" MODIFIED="2010-01-12 16:19:21 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.05706637508870846" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="66.10621435449227" Z="1.9028020848347273">
<NAME>Polyurethane</NAME>
<DICH_DATA CI_END="1.0641931637534325" CI_START="0.014930286122593065" EFFECT_SIZE="0.12605042016806722" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.02702046474309449" LOG_CI_START="-1.8259318694167936" LOG_EFFECT_SIZE="-0.8994557023368495" MODIFIED="2009-10-01 08:50:26 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="1.0884333733475007" STUDY_ID="STD-Albrecht_x002d_Fruh-1998" TOTAL_1="52" TOTAL_2="52" VAR="1.1846872082166198" WEIGHT="66.10621435449227"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.52332135211202" CI_START="1.0178101992013437" DF="0" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="1.0221528327112375" LOG_CI_START="0.007666798506886924" LOG_EFFECT_SIZE="0.5149098156090622" MODIFIED="2009-10-01 12:03:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.046636323049534925" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="33.89378564550774" Z="1.9895881458268267">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="10.523321352112026" CI_START="1.0178101992013435" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.0221528327112377" LOG_CI_START="0.007666798506886828" LOG_EFFECT_SIZE="0.5149098156090622" MODIFIED="2009-10-01 12:03:48 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.5959141182784953" STUDY_ID="STD-AbuRahma-2007" TOTAL_1="100" TOTAL_2="100" VAR="0.3551136363636364" WEIGHT="33.89378564550774"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="28.072900525211537" CI_START="1.306502455547209" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="6.056179775280899" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="1.4482872867710914" LOG_CI_START="0.11611023031256044" LOG_EFFECT_SIZE="0.782198758541826" METHOD="MH" MODIFIED="2009-10-01 12:31:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.0213567199609318" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="2.301618074056125">
<NAME>Stroke or death</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>Other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="28.072900525211537" CI_START="1.306502455547209" DF="0" EFFECT_SIZE="6.056179775280899" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="1.4482872867710914" LOG_CI_START="0.11611023031256044" LOG_EFFECT_SIZE="0.782198758541826" MODIFIED="2009-09-20 10:57:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0213567199609318" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="2.301618074056125">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="28.072900525211537" CI_START="1.306502455547209" EFFECT_SIZE="6.056179775280899" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.4482872867710914" LOG_CI_START="0.11611023031256044" LOG_EFFECT_SIZE="0.782198758541826" MODIFIED="2009-09-15 12:25:08 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.7825273973465234" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="0.6123491275979237" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.539393217859418" CI_END="22.48959587900842" CI_START="3.0269302542234984" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="8.250723493817416" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="4" I2="77.97062400177887" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.3519816515630878" LOG_CI_START="0.4810024141660748" LOG_EFFECT_SIZE="0.9164920328645813" METHOD="MH" MODIFIED="2010-01-12 16:19:09 +0000" MODIFIED_BY="Hazel Fraser" NO="5" P_CHI2="0.03312338374814916" P_Q="0.0" P_Z="3.711170369086471E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="152" WEIGHT="100.0" Z="4.1247627943481895">
<NAME>Arterial occlusion/restenosis &gt; 50%</NAME>
<GROUP_LABEL_1>Dacron</GROUP_LABEL_1>
<GROUP_LABEL_2>Other synthetic material</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="47.21804726427956" CI_START="4.06667406401892" DF="0" EFFECT_SIZE="13.857142857142858" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="3" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="1.6741080225588059" LOG_CI_START="0.6092393659451699" LOG_EFFECT_SIZE="1.141673694251988" MODIFIED="2009-09-20 10:58:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.637991412868395E-5" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="58.56353591160221" Z="4.202657875097112">
<NAME>PTFE</NAME>
<DICH_DATA CI_END="47.21804726427958" CI_START="4.066674064018919" EFFECT_SIZE="13.857142857142858" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="3" LOG_CI_END="1.674108022558806" LOG_CI_START="0.6092393659451699" LOG_EFFECT_SIZE="1.141673694251988" MODIFIED="2009-09-15 12:22:37 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.6255091200797127" STUDY_ID="STD-AbuRahma-2002" TOTAL_1="100" TOTAL_2="100" VAR="0.3912616593028964" WEIGHT="58.56353591160221"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.21338325177231" CI_START="0.013017609920552583" DF="0" EFFECT_SIZE="0.326984126984127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.9145220882901823" LOG_CI_START="-1.885468746459039" LOG_EFFECT_SIZE="-0.4854733290844283" MODIFIED="2009-09-20 11:02:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4967245890762668" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="41.43646408839779" Z="0.6796523964661207">
<NAME>Polyurethane</NAME>
<DICH_DATA CI_END="8.21338325177231" CI_START="0.013017609920552583" EFFECT_SIZE="0.326984126984127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9145220882901823" LOG_CI_START="-1.885468746459039" LOG_EFFECT_SIZE="-0.4854733290844283" MODIFIED="2009-09-20 11:02:11 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="1.6447284765098587" STUDY_ID="STD-Albrecht_x002d_Fruh-1998" TOTAL_1="52" TOTAL_2="52" VAR="2.705131761442441" WEIGHT="41.43646408839779"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-01-12 16:22:00 +0000" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2010-01-12 16:22:00 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-09-10 14:25:30 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-12 16:22:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>MEDLINE 1966 to 1995: term used "carotid endarterectomy"</P>
<P>MEDLINE (Ovid) 1994 to 2008 and Cochrane Central Register of Controlled Trials (lines 1 to 12)</P>
<P>1 Endarterectomy, carotid/<BR/>2 exp carotid arteries/su (surgery)<BR/>3 exp carotid artery diseases/su<BR/>4 exp carotid arteries/<BR/>5 exp carotid artery diseases/<BR/>6 carotid.tw.<BR/>7 4 or 5 or 6<BR/>8 endarterectomy/<BR/>9 (endarterectom$ or surg$).tw.<BR/>10 8 or 9<BR/>11 7 and 10<BR/>12 1 or 2 or 3 or 11<BR/>13 randomized controlled trial.pt.<BR/>14 randomized controlled trials as topic/<BR/>15 controlled clinical trial.pt.<BR/>16 controlled clinical trials as topic/<BR/>17 random allocation/<BR/>18 clinical trial.pt.<BR/>19 exp clinical trials as topic/<BR/>20 (clin$ adj25 trial$).tw.<BR/>21 random$.tw.<BR/>22 research design/<BR/>23 intervention studies/<BR/>24 control$.tw.<BR/>25 patch$.tw.<BR/>26 or/13-25<BR/>27 12 and 26<BR/>28 limit 27 to humans<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-01-12 16:21:47 +0000" MODIFIED_BY="Hazel Fraser" NO="2">
<TITLE MODIFIED="2008-09-10 14:26:07 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-12 16:21:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>EMBASE 1980 to 1995: terms used "carotid endarterectomy" and "carotid surgery"</P>
<P>EMBASE (Ovid) 1994 to 2008</P>
<P>1 carotid endarterectomy/<BR/>2 carotid artery surgery/<BR/>3 exp carotid artery disease/su<BR/>4 exp carotid artery/<BR/>5 exp carotid artery disease/<BR/>6 4 or 5<BR/>7 artery surgery/ or endarterectomy/ or vascular surgery/ or surgery/<BR/>8 6 and 7<BR/>9 (carotid adj5 (endarterect$ or surgery)).tw.<BR/>10 1 or 2 or 3 or 8 or 9<BR/>11 Clinical trial/<BR/>12 randomized controlled trial/<BR/>13 controlled study/<BR/>14 randomization/<BR/>15 random$.tw.<BR/>16 Prospective study/<BR/>17 "Evaluation and follow up"/ or Follow up/<BR/>18 versus.tw.<BR/>19 prospective.tw.<BR/>20 types of study/<BR/>21 methodology/<BR/>22 comparative study/<BR/>23 ((intervention or experiment$) adj5 group$).tw.<BR/>24 Parallel design/<BR/>25 intermethod comparison/<BR/>26 (controls or control group$).tw.<BR/>27 (control$ adj trial$).tw.<BR/>28 patch$.tw.<BR/>29 or/11-28<BR/>30 10 and 29<BR/>31 limit 30 to humans<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>